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REDUCED DYE PROBES FOR THE 
DETECTION OF RADICAL OXYGEN 
SPECIES 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation-in-part of International 
Application No. PCT/US2009/038772, filed on Mar. 30, 
2009, which claims benefit of and priority to U.S. Provisional 
Patent Application No. 61/040,370, filed Mar. 28, 2008 and 
U.S. Provisional Patent Application No. 61/100,897, filed 
Sep. 29, 2008. These applications are incorporated herein by 
reference. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
The invention was made with Government Support under 
Agreement No. 5 UOl HL080711-04 awarded by the 
National Institutes of Health and Grant No. BES-0546962 
awarded to by the National Science Foundation. The Govern-
ment has certain rights in the invention. 
FIELD OF THE INVENTION 
This invention is generally in the field of probes to detect 
radical oxygen species in vitro or in vivo, particularly reduced 
dye probes. 
BACKGROUND OF THE INVENTION 
The development of fluorescent probes for detection of 
reactive oxygen species, such as superoxide and/or hydroxyl 
radicals, is a central problem in the field of chemical biology. 
Reactive oxygen species, such as superoxide and the 
hydroxyl radical, play a significant role in a variety of dis-
eases, such as inflammatory diseases, and probes which can 
detect reactive oxygen species (ROS) in serum samples, live 
tissue explants, cell cultures, and/or in vivo have tremendous 
potential as medical diagnostics and research tools for the 
diagnoses of diseases characterized by increased ROS pro-
duction. 
Fluorescent sensors for superoxide and the hydroxyl radi-
cal have been investigated. For example, dihydroethydium 
(DHE), the structure of which is shown below, has been used 
as an ROS probe. 
Dihydroethidiurn (DHE) 
However, DHE has limited applicability due to its sponta-
neous auto-oxidation, rapid photobleaching, high toxicity, 
and multiple reaction products with ROS. Further, the lower 
emission wavelength ofDHE makes it difficult to use in vivo. 
Dihydrorhodamine, another reduced dye that has been inves-
2 
tigated for detection of ROS, also suffers from high rates of 
aerial oxidation, limiting its applications. 
Sulfonate ester-based dyes have also been investigated as 
ROS probes. However, these probes undergo rapid hydrolysis 
limiting their applications. Moreover, sulfonate ester-based 
dyes typically involve multistep synthetic procedures which 
are time consuming and expensive. 
There exists a need for ROS probes that do not suffer from 
the limitations of prior art probes, such as dihydroethydium, 
10 dihydrorhodamine, and sulfonate ester-based dyes. 
15 
Therefore, it is an object of the invention to provide 
improved probes for the detection of ROS, and methods of 
making and using thereof. 
SUMMARY OF THE INVENTION 
Reduced dyes including, but not limited to, hydrocyanines, 
deuterocyanines, and/or other hydro- or deuterated dyes, such 
as deuterated leuco dyes, capable of detecting one or more 
20 reactive oxygen species, are described herein. The reduced 
dyes are generally prepared by reducing the oxidized dye 
with a reducing agent, such as sodium borohydride or sodium 
borodeuteride. For example, hydrocyanines and deuterohy-
droethydium (D-DHE or DDE) can be synthesized from cya-
25 nine dyes via a one-step reduction using a reducing agent, 
such as sodium borohydride (NaBH4 ) or sodium borodeu-
teride (NaBD4). The reduced dyes exhibit little or no fluores-
cence due to the disrupted it conjugation compared to the 
oxidized dye. However, upon reaction with ROS, the reduced 
30 dyes are oxidized, regenerating the extended it conjugation 
and causing a substantial increase in fluorescence intensity, 
compared to the reduced dye, when exposed to radiation of 
sufficient wavelength. For example, Hydro-IR-676 exhibits 
negligible fluorescence; however, upon oxidation by ROS 
35 (e.g., superoxide), IR-676 exhibits a 100-fold increase in 
fluorescence emission O'-ex=675 nm. "-em=693 nm). 
In many cases, the oxidized dye starting material is mem-
brane impermeable. However, upon reduction, many of the 
reduced dyes are membrane permeable. Thus, reduced dyes 
40 can accumulate in cells and/or tissue. Once inside the cell or 
tissue, the reduced dye is reoxidized upon reaction with ROS, 
and the oxidized dye again becomes membrane impermeable, 
trapping the dye within the cell. For example, oxidized cya-
nine starting materials are generally membrane impermeable. 
45 However, upon reduction, many of the hydrocyanines and/or 
deuterocyanines are membrane permeable. Thus, hydrocya-
nines and/or reduced cyanines can accumulate in cells and/or 
tissue. 
In one embodiment, the reduced dye is a cyanine dye. Any 
50 cyanine dye can be reduced to form a hydrocyanine or deu-
terocyanine suitable for the compositions and methods of use 
thereof described herein. In one embodiment, the cyanine dye 
is fluorescent, but upon reduction, is weakly fluorescent com-
pared to the oxidized dye. In a preferred embodiment, the 
55 reduced dye is negligibly fluorescent and membrane perme-
able, while the oxidized dye is substantially more fluorescent 
and is membrane impermeable. In another embodiment, the 
reduced cyanine is negligibly fluorescent, the oxidized cya-
nine is substantially more fluorescent, and both the reduced 
60 cyanine and the oxidized cyanine are membrane imperme-
able. Upon oxidation by one or more reactive oxygen species, 
the fluorescence quantum yield increases significantly due to 
the regeneration of the extended it conjugation. 
In another embodiment, the reduced dye is a deuterocya-
65 nine or other deuterated dye. A deuterated reduced dye is a 
dye that has been reduced by a deuterated reducing agent, 
thereby incorporating deuterium into the reduced cyanine 
US 8,628,753 B2 
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dye. In one embodiment, the deuterated reduced dye is a 
deuterocyanine. Although the hydrocyanines exhibit excel-
lent stability to auto-oxidation in aqueous solutions, their 
background oxidation in cell cultures can be improved. The 
stability of the dyes can be improved by replacing their oxi-
dazable hydrogens with deuterium. Deuterocyanines will 
likely be more stable to auto-oxidation and exhibit lower 
levels of background fluorescence in cell cultures than the 
corresponding hydrocyanines. Oxidation of deuterocyanines 
generates the identical cyanine dye as their hydrogen ana- 10 
!agues, allowing these probes to be used with existing proto-
cols for ROS sensors. 
The reduced dyes can be used to image ROS, such as 
hydroxide radical and superoxide, in vitro, such as in serum, 
cells, cell cultures, tissue explants, etc., as well as in vivo, 15 
such as in cells, tissues, organs, bodily fluids, and combina-
tions thereof. The reduced dyes described herein possess 
excellent stability to auto-oxidation, have tunable emission 
wavelengths, and picomolar to millimolar sensitivity. In one 
embodiment, the reduced dyes have at least nanomolar (e.g., 20 
1-50 nM, preferably 1-30 nM, more preferably 5-30 nM) 
sensitivity to ROS. The cyanine dyes described herein have 
emission wavelengths from 500-1100 nm (into the near infra-
red), which is significantly higher than DHE or sulfonate 
ester-based dyes, and thus have potential for in vivo applica- 25 
tions. This is an important feature since most fluorescent dyes 
are not effective in vivo since their emission wavelengths are 
absorbed by surrounding tissue. 
4 
(one end group is an open chain or linear moiety and the other 
group is a cyclic moiety). The cyclic moiety can be aromatic 
or non-aromatic. The linear and/or cyclic moieties can be 
unsubstituted or substituted at one or more positions. The 
streptocyanines, closed chain cyanines, and/or hemocyanines 
can be symmetrical (i.e., end groups are identical) or asym-
metrical (i.e., end groups are different). 
"Reduced cyanine dye" and "Hydrocyanine" or "Deutero-
cyanine" are used interchangeably and generally refer to a 
cyanine dye wherein the iminium cation has been reduced. 
"Deuterocyanine", as used herein, refers to a cyanine dye that 
has been reduced by a deuterated reducing agent, thus incor-
porating deuterium into the reduced molecule. Examples of 
reduced iminium cations are shown below. 
"Reactive oxygen species" and "ROS" are used inter-
changeably and refer to molecules orions that contain oxygen 
ions, free radicals, peroxides, or combinations thereof. Reac-
tive oxygen species can be organic or inorganic. Examples of 
reactive oxygen species include, but are not limited to, super 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph showing the fluorescence intensity (RFU/ 
S) ofhydro-IR-676 andhydro-IR-676+K02 (superoxide) as a 
function of wavelength (nm). 
30 oxides; free radicals, such as hydroxyl radicals and peroxyl 
radicals; peroxides, singlet oxygen, ozone, nitrogen monox-
ide; anions, such as hydroxyl anions and superoxide anions; 
hypochlorus acid; peroxynitrites; and combinations thereof. 
In one embodiment, the reduced molecules are selectively 
FIG. 2 is a graph comparing the stability to auto-oxidation 
ofDHE (%intact) and D-DHE in solution (FIG. 2a) and as a 
solid (FIG. 2b) as a function of time (days). 
FIG. 3a is a graph comparing the intensity of the fluores-
cence (relative fluorescence units, RFU/S) of hydro-Cy3, 
hydro-Cy7, and DHE as a function of hydroxyl radical con-
centration (nM). FIG. 3b is a graph showing the intensity of 
the fluorescence of hydro-ICG (RFU/s) as a function of 
hydroxyl radical concentration (nM). 
FIG. 4 is a graph comparing the intensity of the fluores-
cence (relative fluorescence units, RFU/S) ofDHE and DDE 
as a function of hydrogen peroxide concentration (nM) in 
Fenton's reagent. 
FIG. 5 is a bar graph showing the sensitivity ofhydro-Cy7 
(intensity, RFU/s) to various reactive oxygen species. 
35 sensitive to the presence of hydroxide radical, superoxide, 
metal-hydrogen peroxide complexes, such as iron-hydrogen 
peroxide, and combinations thereof. 
"Weakly fluorescent" and "negligibly fluorescent" are 
used interchangeably and generally refers to a fluorescence 
40 measurement of less than 10 relative fluorescence units per 
second (RFU/S). 
"Substantially more fluorescent" as used herein, generally 
means a fluorescence measurement of greater than 10 RFU/S, 
preferably greater than 20 RFU/S compared to the fluores-
45 cence intensity of a reduced dye. In one embodiment, the 
fluorescence measurement is from about 20 RFU/S to about 
1000 RFU/S. In another embodiment, the oxidized dye will 
increase its fluorescence by at least about 10% compared to 
the reduced dye after reaction with ROS. 
FIG. 6 is a graph comparing the stability to auto-oxidation 50 
(%intact) ofhydro-Cy3, hydro-Cy7, and DHE as a function 
"Membrane permeable" as used herein, refers to a mol-
ecule which can enter a cell through passive diffusion. Gen-
erally, membrane permeable molecules generally have a Log 
P of0.5 or greater (Log P=Log(C0 ctan)Cwater). 
of time (hours). 
FIG. 7 is a graph comparing the fluorescent intensity (RFU I 
S) of hydro-Cy7+saline (white bar) and hydro-Cy7+LPS 
(dark bar). 
DETAILED DESCRIPTION OF THE INVENTION 
I. Definitions 
"Reduced dye", as used herein, refers to a dye molecule in 
which one or more it-bonds have been reduced, disrupting the 
extended it-conjugation, resulting in a molecule that exhibits 
negligible or no fluorescence. 
"Cyanine dye", as used herein, includes streptocyanines 
(end groups are open chain or linear moieties), closed chain 
cyanines (end groups are cyclic moieties), and hemicyanines 
"Membrane impermeable" as used herein, generally refers 
55 to a molecule that cannot diffuse through a cell membrane by 
passive diffusion either because it is too hydrophilic, too large 
or bound to an intracellular or extracellular organelle. 
"Ary!", as used herein, refers to C5 -C10-membered aro-
matic, heterocyclic, fused aromatic, fused heterocyclic, 
60 biaromatic, or bihetereocyclic ring systems. Broadly defined, 
"aryl", as used herein, includes 5-, 6-, 7-, 8-, 9-, and IO-mem-
bered single-ring aromatic groups that may include from zero 
to four heteroatoms, for example, benzene, pyrrole, furan, 
thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, 
65 pyridine, pyrazine, pyridazine and pyrimidine, and the like. 
Those aryl groups having heteroatoms in the ring structure 
may also be referred to as "aryl heterocycles" or "heteroaro-
US 8,628,753 B2 
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matics". The aromatic ring can be substituted at one or more 
ring positions with one or more substituents including, but not 
limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, 
cycloalkyl, hydroxyl, alkoxyl, amino (or quatemized amino), 
nitro, sulfhydryl, imino, amino, phosphonate, phosphinate, 
carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfona-
mido, ketone, aldehyde, ester, heterocyclyl, aromatic or het-
eroaromatic moieties, -CF3 , --CN; and combinations 
thereof. 
6 
heteroalkyls. Suitable substituents include, but are not limited 
to, halogens, such as fluorine, chlorine, bromine, or iodine; 
hydroxyl; -NR1 R2 , wherein R1 and R2 are independently 
hydrogen, alkyl, or aryl, and wherein the nitrogen atom is 
optionally quatemized; -SR, wherein R is hydrogen, alkyl, 
or aryl; --CN; -N02 ; --COOR; carboxylate; -COR, 
--COOR, or --CONR2 , wherein R is hydrogen, alkyl, or 
aryl; azide, aralkyl, alkoxyl, imino, phosphonate, phosphi-
nate, silyl, ether, sulfonyl, sulfonamido, heterocyclyl, aro-
The term "aryl" also includes polycyclic ring systems hav-
ing two or more cyclic rings in which two or more carbons are 
common to two adjoining rings (i.e., "fused rings") wherein 
10 matic or heteroaromatic m01et1es, -CF3 ; -CN; 
-NCOCOCH2 CH2 ; -NCOCOCHCH; -NCS; and com-
binations thereof. 
at least one of the rings is aromatic, e.g., the other cyclic ring 
or rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, 
aryls and/or heterocycles. Examples of heterocyclic rings 15 
include, but are not limited to, benzimidazolyl, benzofuranyl, 
benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzox-
azolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, ben-
zisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 
4aH carbazolyl, carbolinyl, chromanyl, chromenyl, cinnoli- 20 
nyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydro-
furo[2,3 b ]tetrahydrofuran, furanyl, furazanyl, imidazolidi-
nyl, imidazolinyl, imidazolyl, lH-indazolyl, indolenyl, 
indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isoben-
zofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoin- 25 
dolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenediox-
yphenyl, morpholinyl, naphthyridinyl, 
octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2, 
4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazo-
lidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, 30 
phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, 
phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperi-
donyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, 
pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, 
pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, 35 
pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, 
pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinox-
alinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquino-
linyl, tetrahydroquinolinyl, tetrazolyl, 61'-1,2,5-thiadiazinyl, 
1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3, 40 
4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiaz-
olyl, thienooxazolyl, thienoimidazolyl, thiophenyl and xan-
thenyl. One or more of the rings can be substituted as defined 
above for "aryl". 
"Alkyl", as used herein, refers to the radical of saturated or 45 
unsaturated aliphatic groups, including straight-chain alkyl, 
alkenyl, or alkynyl groups, branched-chain alkyl, alkenyl, or 
alkynyl groups, cycloalkyl, cycloalkenyl, or cycloalkynyl 
(alicyclic) groups, alkyl substituted cycloalkyl, cycloalkenyl, 
or cycloalkynyl groups, and cycloalkyl substituted alkyl, alk- 50 
enyl, or alkynyl groups. Unless otherwise indicated, a straight 
chain or branched chain alkyl has 30 or fewer carbon atoms in 
its backbone (e.g., Cl-C30 for straight chain, C3-C30 for 
branched chain), preferably 20 or fewer, more preferably 10 
or fewer, most preferably 6 or fewer. If the alkyl is unsatur- 55 
ated, the alkyl chain generally has from 2-30 carbons in the 
chain, preferably from 2-20 carbons in the chain, more pref-
erably from 2-10 carbons in the chain. Likewise, preferred 
cycloalkyls have from 3-20 carbon atoms in their ring struc-
ture, preferably from 3-10 carbons atoms in their ring struc- 60 
ture, most preferably 5, 6 or 7 carbons in the ring structure. 
The terms "alkenyl" and "alkynyl" refer to unsaturated 
aliphatic groups analogous in length and possible substitution 
The term "heteroalkyl", as used herein, refers to straight or 
branched chain, or cyclic carbon-containing radicals, or com-
binations thereof, containing at least one heteroatom. Suit-
able heteroatoms include, but are not limited to, 0, N, Si, P 
and S, wherein the nitrogen, phosphorous and sulfur atoms 
are optionally oxidized, and the nitrogen heteroatom is 
optionally quaternized. 
Examples of saturated hydrocarbon radicals include, but 
are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, 
t-butyl, isobutyl, sec-butyl, cyclohexyl, ( cyclohexyl)methyl, 
cyclopropylmethyl, and homologs and isomers of, for 
example, n-pentyl, n-hexyl, n-heptyl, n-octyl. Examples of 
unsaturated alkyl groups include, but are not limited to, vinyl, 
2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-penta-
dienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, and 
3-butynyl. 
"Alkoxy", "alkylamino", and "alkylthio" are used herein in 
their conventional sense, and refer to those alkyl groups 
attached to the remainder of the molecule via an oxygen atom, 
an amino group, or a sulfur atom, respectively. 
"Alkylaryl", as used herein, refers to an alkyl group sub-
stituted with an aryl group (e.g., an aromatic or hetero aro-
matic group). 
"Heterocycle" or "heterocyclic", as used herein, refers to a 
cyclic radical attached via a ring carbon or nitrogen of a 
monocyclic or bicyclic ring containing 3-10 ring atoms, and 
preferably from 5-6 ring atoms, consisting of carbon and one 
to four heteroatoms each selected from the group consisting 
of non-peroxide oxygen, sulfur, and N(Y) wherein Y is absent 
or is H, 0, (c1 _10)alkyl, phenyl or benzyl, and optionally 
containing 1-3 double bonds and optionally substituted with 
one or more substituents. Examples of heterocyclic ring 
include, but are not limited to, benzimidazolyl, benzofuranyl, 
benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzox-
azolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, ben-
zisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 
4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnoli-
nyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydro-
furo[2,3-b ]tetrahydrofuran, furanyl, furazanyl, imidazolidi-
nyl, imidazolinyl, imidazolyl, lH-indazolyl, indolenyl, 
indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isoben-
zofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoin-
dolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenediox-
yphenyl, morpholinyl, naphthyridinyl, 
octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2, 
4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazo-
lidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, 
phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, 
phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperi-
donyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, 
pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, 
pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, to the alkyls described above, but that contain at least one 
double or triple bond respectively. 
The term "alkyl" includes one or more substitutions at one 
or more carbon atoms of the hydrocarbon radical as well as 
65 pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, 
pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinox-
alinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquino-
US 8,628,753 B2 
7 
liny I, tetrahydroquinoliny I, tetrazoly I, 6H-1,2, 5-thiadiaziny I, 
1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3, 
4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiaz-
olyl, thienooxazolyl, thienoimidazolyl, thiophenyl and xan-
thenyl. Heterocyclic groups can optionally be substituted 
with one or more substituents as defined above for alkyl and 
aryl. 
"Halogen", as used herein, refers to fluorine, chlorine, 
bromine, or iodine. 
8 
A. Reduced Cyanine Dyes 
Any cyanine dye can be reduced to form a hydrocyanine or 
deueterocyanine suitable for the compositions and methods 
of use thereof described herein. The cyanine dye can be an 
asymmetrical dye or a symmetrical dye. In one embodiment, 
the cyanine dye is fluorescent, but upon reduction, is weakly 
fluorescent compared to the oxidized dye. In a preferred 
embodiment, the reduced dye is negligibly fluorescent, com-
pared to the oxidized dye, and membrane permeable, while 
As generally used herein "pharmaceutically acceptable" 
refers to those compounds, materials, compositions, and/or 
dosage forms which are, within the scope of sound medical 
judgment, suitable for use in contact with the tissues, organs, 
and/or bodily fluids of human beings and animals without 
excessive toxicity, irritation, allergic response, or other prob-
lems or complications commensurate with a reasonable ben-
efit/risk ratio. 
10 the oxidized dye is substantially more fluorescent and is 
membrane impermeable. In another embodiment, the 
reduced cyanine is negligibly fluorescent compared to the 
oxidized dye, the oxidized cyanine is substantially more fluo-
rescent than the reduced dye, and both the reduced cyanine 
The compounds described herein may exist in unsolvated 
forms as well as solvated forms, including hydrated forms. In 
general, the solvated forms are equivalent to unsolvated 
forms and are within the scope of the compounds described 
herein. The compounds described herein may exist in mul-
tiple crystalline or amorphous forms. In general, all physical 
forms are equivalent for the uses described herein and are 
intended to be within the scope of the compounds described 
herein. 
15 and the oxidized cyanine are membrane impermeable. Upon 
oxidation by a reactive oxygen species, the fluorescence 
quantum yield increases dramatically due to the regeneration 
of the extended it conjugation. 
In another embodiment, the reduced dye is a deuterocya-
20 nine or other deuterated dye. A deuterated reduced dye is a 
dye that has been reduced by a deuterated reducing agent, 
thus incorporating deuterium into the reduced dye. Although 
the hydrocyanines exhibit excellent stability to auto-oxida-
tion in aqueous solutions, compared to prior art ROS probes 
The compounds described herein may possess asymmetric 
carbon atoms (chiral centers) or double bonds; the racemates, 
diastereomers, geometric isomers and individual isomers are 
within the scope of the compounds described herein. The 
compounds described herein may be prepared as a single 
isomer or as a mixture of isomers. In one, the compounds are 
prepared as a single isomer, substantially separated from 
other isomers. Methods of preparing substantially isomeri-
cally pure compounds are known in the art. 
25 such as DHE and sulfonate ester-based dyes, their back-
ground oxidation in cell cultures can be improved. The sta-
bility of the dyes can be improved by replacing their oxidiz-
able hydrogens with deuterium. Deuterocyanines will likely 
be more stable to auto-oxidation and exhibit lower levels of 
30 background fluoresecence in cell cultures compared to hydro-
cyanine. 
35 
II. Compounds 
Reduced dyes including, but not limited to, hydrocyanines, 
deuterocyanines, and/or other hydro- or deuterated dyes, such 40 
as deuterated leuco dyes, capable of detecting one or more 
reactive oxygen species, are described herein. The reduced 
dyes are generally prepared by reducing the oxidized dye 
with a reducing agent, such as sodium borohydride or sodium 
borodeuteride. For example, hydrocyanines can be synthe- 45 
sized from cyanine dyes via a one-step reduction using a 
reducing agent, such as sodium borohydride (NaBH4 ) or 
sodium borodeuteride (NaBD4 ). The reduced dyes exhibit 
little or no fluorescence, compared to the oxidized dye, due to 
the disrupted it conjugation. However, upon reaction with 50 
ROS, the reduced dyes are oxidized, regenerating the 
extended it conjugation and causing a substantial increase in 
fluorescence intensity, compared to the reduced dye, when 
exposed to radiation of a sufficient wavelength. 
For example, Hydro-IR-676 exhibits negligible fluores- 55 
cence; however, upon oxidation by ROS (e.g., superoxide ), 
IR-676 exhibits a 100-fold increase in fluorescence emission 
O'-ex =675 nm. "-em =693 nm). This is illustrated in FIG. 1. 
In the case of the cyanines, the oxidized cyanine starting 
material is generally membrane impermeable. However, 60 
upon reduction, many of the hydrocyanines are membrane 
permeable. Thus, reduced dyes can accumulate in cells and/or 
tissue. Once inside the cell or tissue, the reduced dye is 
reoxidized upon reaction with ROS, and the oxidized dye 
again becomes membrane impermeable, trapping the dye 65 
within the cell. This allows for the accumulation of the probes 
with cells or tissue, which can serve to amplify the signal. 
Exemplary reduced dyes include, but are not limited to, 
(a) 
wherein x is hydrogen; halogen; cl-20 alkyl, preferably 
cl-10 alkyl, more preferably cl-6 alkyl, most preferably cl, 
C2 or C3 alkyl; aryl; -OR, where R is C1 _20 alkyl, preferably 
C1_10 alkyl, more preferably C1 _6 alkyl, or aryl; hydroxyl; 
-NR5 R6 , where R5 and R6 are independently hydrogen, 
cl-20 alkyl, preferably cl-10 alkyl, more preferably cl-6 alkyl, 
most preferably C1 , C2 or C3 alkyl, or aryl; -CN, -SH; 
-N02 ; -S---C1 _20 alkyl, preferably C1 _10 alkyl, more pref-
erably C1 _6 alkyl, most preferably C1 , C2 or C3 alkyl; -S-
ary!; aryl, -COOH; ---COH; -COR or --COOR, where R 
is defined above; or -CONR13R14, wherein R13 and R14 are 
independently hydrogen or R as defined above; 
R1 -R4 are independently hydrogen, C1 _20 alkyl, preferably 
cl-10 alkyl, more preferably cl-6 alkyl, most preferably cl, 
C2 or C3 alkyl; C1 _20 alkyl sulfonate, preferably C1_10 alkyl 
sulfonate, more preferably C1 _6 alkyl sulfonate, most prefer-
ably Cu C2 , C3 , or C4 alkyl sulfonate; C1_20 alkyl carboxylic 
acid or carboxylate, preferably C1_10 alkyl carboxylic acid or 
carboxylate, more preferably C1_6 alkyl carboxylic acid or 
carboxylate, most preferably C1 , C2 , C3 , or C4 alkyl carboxy-
lic acid or carboxylate; cl-20 alkyl amino, preferably cl-10 
alkyl amino or quatemized amino, more preferably C1 _6 alkyl 
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amino or quaternized amino, most preferably Cu C2 , C3 , or 
C4 alkyl amino or quaternized amino; aryl, benzyl, oligoeth-
ylene glycol, or polyethylene glycol; 
Rs and R6 are independently hydrogen; hydroxyl; -NH2 , 
-OR7 ; -NHR8 ; -NR9 R10, C1_20 alkyl, preferably C1_10 5 
alkyl, more preferably C1 _6 alkyl, most preferably Cu C2 or 
C3 alkyl; C1 _20 alkyl sulfonate, preferably C1 _10 alkyl sul-
fonate, more preferably C1_6 alkyl sulfonate, most preferably 
C1 , C2 , C3 , or C4 alkyl sulfonate; C1_20 alkyl carboxylic acid 
or carboxylate, preferably C1 _10 alkyl carboxylic acid or car- 10 
boxylate, more preferably C1_6 alkyl carboxylic acid or car-
boxylate, most preferably Cu C2 , C3 , or C4 alkyl carboxylic 
acid or carboxylate; C1_20 alkyl amino or quaternized amino, 
preferably C1_10 alkyl amino or quaternized amino, more 
preferably C1 _6 alkyl amino or quaternized amino, most pref- 15 
erably Cu C2 , C3 , or C4 alkyl amino; -COOH; -C02 -; or 
-So3-; wherein R7 -R10 are the same as R; oligoethylene 
glycol, or polyethylene glycol; 
n is an integer from 1-5; 
R12 is H or D; and 
the benzene ring represented by dotted lines is optional; 
(b) 
20 
25 
10 
boxylate, more preferably C1_6 alkyl carboxylic acid or car-
boxylate, most preferably Cu C2 , C3 , or C4 alkyl carboxylic 
acid or carboxylate; C1_20 alkyl amino or quaternized amino, 
preferably C1_10 alkyl amino or quaternized amino, more 
preferably C1 _6 alkyl amino or quaternized amino, most pref-
erably C1 , C2 , C3 , or C4 alkyl amino or quaternized amino; 
--COOH;-Co2-; or-S03-; whereinR9 -R12 arethe same 
as R; oligoethylene glycol, or polyethylene glycol; 
n is an integer from 1-5; 
R11 is Hor D, and 
the benzene ring represented by dotted lines is optional. 
(c) 
wherein x is hydrogen; halogen; cl-20 alkyl, preferably 
cl-10 alkyl, more preferably cl-6 alkyl, most preferably cl, 
C2 or C3 alkyl; aryl; -OR, where R is C1 _20 alkyl, preferably 
30 C1_10 alkyl, more preferably C1 _6 alkyl, or aryl; hydroxyl; 
-NRsR6 , where Rs and R6 are independently hydrogen, 
cl-20 alkyl, preferably cl-10 alkyl, more preferably cl-6 alkyl, 
most preferably C1 , C2 or C3 alkyl, or aryl; -CN, -SH; 
-N02 ; -S--C1 _20 alkyl, preferably C1 _10 alkyl, more pref-
wherein x is hydrogen; halogen; cl-20 alkyl, preferably 
cl-10 alkyl, more preferably cl-6 alkyl, most preferably cl, 
C2 or C3 alkyl; aryl; -OR, where R is C1 _20 alkyl, preferably 
C1 _10 alkyl, more preferably C1 _6 alkyl, or aryl; hydroxyl; 
-NRsR6 , where Rs and R6 are independently hydrogen, 
cl-20 alkyl, preferably cl-10 alkyl, more preferably cl-6 alkyl, 
most preferably Cu C2 or C3 alkyl, or aryl; -CN, -SH; 
-N02 ; -S-C1_20 alkyl, preferably C1 _10 alkyl, more pref-
erably C1 _6 alkyl, most preferably Cu C2 or C3 alkyl; -S-
ary!; aryl, -COOH; --COH; -COR or -COOR, where R 
35 erably C1 _6 alkyl, most preferably C1 , C2 or C3 alkyl; -S-
ary!; aryl, -COOH; --COH; -COR or -COOR, where R 
is defined above; or-CONR12R13 , wherein R12 and R13 are 
independently hydrogen or R as defined above; 
R1 and R2 are independently hydrogen, C1_20 alkyl, prefer-
40 
ably cl-10 alkyl, more preferably cl-6 alkyl, most preferably 
is defined above; or --CONR12R13, wherein R12 and R13 are 45 
independently hydrogen or R as defined above; 
Cu C2 or C3 alkyl; C1 _20 alkyl sulfonate, preferably C1_10 
alkyl sulfonate, more preferably C1 _6 alkyl sulfonate, most 
preferably C1 , C2 , C3 , or C4 alkyl sulfonate; C1 _20 alkyl car-
boxylic acid or carboxylate, preferably C1 _10 alkyl carboxylic 
acid or carboxylate, more preferably C1 _6 alkyl carboxylic 
acid or carboxylate, most preferably C1 , C2 , C3 , or C4 alkyl 
carboxylic acid or carboxylate; C1 _20 alkyl amino, preferably 
50 C1_10 alkyl amino orquaternizedamino, morepreferablyC1 _6 
alkyl amino or quaternized amino, most preferably cl, c2, 
R1 and R2 are independently hydrogen, C1 _20 alkyl, prefer-
ably cl-10 alkyl, more preferably cl-6 alkyl, most preferably 
C1 , C2 or C3 alkyl; C1 _20 alkyl sulfonate, preferably C1_10 
alkyl sulfonate, more preferably C1_6 alkyl sulfonate, most 
preferably C1 , C2 , C3 , orC4 alkyl sulfate of sulfite; C1 _20 alkyl 
carboxylic acid or carboxylate, preferably C1 _10 alkyl car-
boxylic acid or carboxylate, more preferably C1 _6 alkyl car-
boxylic acid or carboxylate, most preferably C1 , C2 , C3 , or C4 
alkyl carboxylic acid or carboxylate; C1_20 alkyl amino or 55 
quaternized amino, preferably C1 _10 alkyl amino or quater-
nized amino, more preferably C1_6 alkyl amino or quaternized 
amino, most preferably C1 , C2 , C3 , or C4 alkyl amino or 
quaternized amino; aryl, benzyl, oligoethylene glycol, or 
polyethylene glycol; 
R3 and R4 are independently hydrogen; hydroxyl; -NH2 , 
-0~; -NHR10 ; -NR11R12, C1 _20 alkyl, preferably C1_10 
alkyl, more preferably C1 _6 alkyl, most preferably Cu C2 or 
C3 , or C4 alkyl amino or quaternized amino; aryl, benzyl, 
oligoethylene glycol, or polyethylene glycol; and 
R3 and R4 are independently hydrogen; hydroxyl; -NH2 , 
---OR9 ; -NHR10; -NR11 R12, C1 _20 alkyl, preferably C1_10 
alkyl, more preferably C1 _6 alkyl, most preferably C1 , C2 or 
C3 alkyl; C1 _20 alkyl sulfonate, preferably C1 _10 alkyl sul-
fonate, more preferably C1 _6 alkyl sulfonate, most preferably 
60 Cu C2 , C3 , or C4 alkyl sulfonate; C1 _20 alkyl carboxylic acid 
or carboxylate, preferably C1 _10 alkyl carboxylic acid or car-
boxylate, more preferably C1_6 alkyl carboxylic acid or car-
boxylate, most preferably Cu C2 , C3 , or C4 alkyl carboxylic 
C3 alkyl; C1 _20 alkyl sulfonate, preferably C1 _10 alkyl sul-
fonate, more preferably C1_6 alkyl sulfonate, most preferably 65 
C1 , C2 , C3 , or C4 alkyl sulfonate; C1_20 alkyl carboxylic acid 
acid or carboxylate; C1_20 alkyl amino or quaternized amino, 
preferably C1_10 alkyl amino or quaternized amino, more 
preferably C1 _6 alkyl amino or quaternized amino, most pref-
or carboxylate, preferably C1 _10 alkyl carboxylic acid or car- erably C1 , C2 , C3 , or C4 alkyl amino or quaternized amino; 
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-COOH; ---C02 -; or-S03 -; wherein R9 -R12 are the same 
as R; oligoethylene glycol, or polyethylene glycol; 
n is an integer from 1-5; 
R11 is Hor D; and 
the benzene ring represented by dotted lines is optional; 
(d) 
wherein x is hydrogen; halogen; cl-20 alkyl, preferably 
cl-10 alkyl, more preferably cl-6 alkyl, most preferably cl, 
C2 or C3 alkyl; aryl; -OR, where R is C1 _20 alkyl, preferably 
C1 _10 alkyl, more preferably C1 _6 alkyl, or aryl; hydroxyl; 
-NRsR6 , where Rs and R6 are independently hydrogen, 
cl-20 alkyl, preferably cl-10 alkyl, more preferably cl-6 alkyl, 
most preferably Cu C2 or C3 alkyl, or aryl; -CN, -SH; 
-N02 ; -S-C1_20 alkyl, preferably C1 _10 alkyl, more pref-
erably C1 _6 alkyl, most preferably Cu C2 or C3 alkyl; -S-
ary!; aryl, -COOH; ---COH; -COR or --COOR, where R 
is defined above; or---CONR17R1 s, wherein R17 and R1 s are 
independently hydrogen or R as defined above; 
R1 and R2 are independently hydrogen, C1 _20 alkyl, prefer-
ably cl-10 alkyl, more preferably cl-6 alkyl, most preferably 
C1 , C2 or C3 alkyl; C1 _20 alkyl sulfonate, preferably C1_10 
alkyl sulfonate, more preferably C1_6 alkyl sulfonate, most 
preferably C1 , C2 , C3 , orC4 alkyl sulfate of sulfite; C1 _20 alkyl 
10 
n is an integer from 1-5; 
R16 is Hor D; and 
12 
the benzene ring represented by dotted lines is optional; 
(e) 
15 wherein x is hydrogen; halogen; cl-20 alkyl, preferably 
cl-10 alkyl, more preferably cl-6 alkyl, most preferably cl, 
C2 or C3 alkyl; aryl; -OR, where R is C1 _20 alkyl, preferably 
C1_10 alkyl, more preferably C1 _6 alkyl, or aryl; hydroxyl; 
-NRsR6 , where Rs and R6 are independently hydrogen, 
cl-20 alkyl, preferably cl-10 alkyl, more preferably cl-6 alkyl, 
20 most preferably C1 , C2 or C3 alkyl, or aryl; -CN, -SH; 
-N02 ; -S---C1 _20 alkyl, preferably C1 _10 alkyl, more pref-
erably C1 _6 alkyl, most preferably C1 , C2 or C3 alkyl; -S-
ary!; aryl, -COOH; ---COH; -COR or --COOR, where R 
is defined above; or-CONR16R17, wherein R16 andR17 are 
25 independently hydrogen or R as defined above; 
R1 and R2 are independently hydrogen, C1_20 alkyl, prefer-
ably cl-10 alkyl, more preferably cl-6 alkyl, most preferably 
Cu C2 or C3 alkyl; C1 _20 alkyl sulfonate, preferably C1_10 
alkyl sulfonate, more preferably C1 _6 alkyl sulfonate, most 
30 preferably C1 , C2 , C3 , or C4 alkyl sulfonate; C1 _20 alkyl car-boxylic acid or carboxylate, preferably C1 _10 alkyl carboxylic 
acid or carboxylate, more preferably C1 _6 alkyl carboxylic 
acid or carboxylate, most preferably C1 , C2 , C3 , or C4 alkyl 
carboxylic acid or carboxylate; C1_20 alkyl amino or quater-
nized amino, preferably C1 _10 alkyl amino or quatemized 
35 amino, more preferably C1 _6 alkyl amino or quatemized 
amino, most preferably C1 , C2 , C3 , or C4 alkyl amino or 
quatemized amino; aryl, benzyl, oligoethylene glycol, or 
polyethylene glycol; 
carboxylic acid or carboxylate, preferably C1 _10 alkyl car-
boxylic acid or carboxylate, more preferably C1 _6 alkyl car- 40 
R3 and R4 are independently hydrogen; hydroxyl; -NH2 , 
---OR9 ; -NHR10; -NR11 R12, C1 _20 alkyl, preferably C1_10 
alkyl, more preferably C1 _6 alkyl, most preferably C1 , C2 or 
C3 alkyl; C1 _20 alkyl sulfonate, preferably C1 _10 alkyl sul-
fonate, more preferably C1 _6 alkyl sulfonate, most preferably 
Cu C2 , C3 , or C4 alkyl sulfonate; C1 _20 alkyl carboxylic acid 
boxylic acid or carboxylate, most preferably C1 , C2 , C3 , or C4 
alkyl carboxylic acid or carboxylate; C1_20 alkyl amino, pref-
erably C1_10 alkyl amino or quatemized amino, more prefer-
ably C1_6 alkyl amino or quaternized amino, most preferably 45 
C1 , C2 , C3 , or C4 alkyl amino or quaternized amino; aryl, 
benzyl, oligoethylene glycol, or polyethylene glycol; and 
or carboxylate, preferably C1 _10 alkyl carboxylic acid or car-
boxylate, more preferably C1_6 alkyl carboxylic acid or car-
boxylate, most preferably Cu C2 , C3 , or C4 alkyl carboxylic 
acid or carboxylate; C1_20 alkyl amino or quatemized amino, 
preferably C1_10 alkyl amino or quatemized amino, more 
preferably C1 _6 alkyl amino or quaternized amino, most pref-
R3 and R4 are independently hydrogen; hydroxyl; -NH2 , 
-0~; -NHR10 ; -NR11R12, C1 _20 alkyl, preferably C1_10 
alkyl, more preferably C1 _6 alkyl, most preferably Cu C2 or 50 erably C1 , C2 , C3 , or C4 alkyl amino or quatemized amino; 
---COOH;-Co2-; or-S03-; whereinR9 -R12 arethe same 
as R; oligoethylene glycol, or polyethylene glycol; C3 alkyl; C1 _20 alkyl sulfonate, preferably C1 _10 alkyl sul-
fonate, more preferably C1_6 alkyl sulfonate, most preferably 
C1 , C2 , C3 , or C4 alkyl sulfonate; C1 _20 alkyl sulfonate, pref-
erably C1 _10 alkyl carboxylic acid or carboxylate, more pref-
erably C1 _6 alkyl carboxylic acid or carboxylate, most pref-
erably C1 , C2 , C3 , or C4 alkyl carboxylic acid or carboxylate; 
cl-20 alkyl amino or quaternized amino, preferably cl-10 
alkyl amino or quaternized amino, more preferably C1_6 alkyl 
amino or quaternized amino, most preferably Cu C2 , C3 , or 60 
C4 alkyl amino or quaternized amino; -COOH; -Co2-or 
-S03 -; wherein R9 -R12 are the same as R; oligoethylene 
glycol, or polyethylene glycol; 
Rs-Rs are independently hydrogen or C1 _20 alkyl, prefer-
ably cl-10 alkyl, more preferably cl-6 alkyl, most preferably 
55 Cu C2 or C3 alkyl; 
Rs-Rs are independently hydrogen or C1 _20 alkyl, prefer- 65 
ably cl-10 alkyl, more preferably cl-6 alkyl, most preferably 
C1 , C2 or C3 alkyl; 
R1s is Hor D; and 
n is an integer from 1-5; 
(f) 
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wherein x is hydrogen; halogen; cl-20 alkyl, preferably 
cl-10 alkyl, more preferably cl-6 alkyl, most preferably cl, 
C2 or C3 alkyl; aryl; -OR, where R is C1 _20 alkyl, preferably 
C1 _10 alkyl, more preferably C1 _6 alkyl, or aryl; hydroxyl; 
-NRsR6 , where Rs and R6 are independently hydrogen, 
cl-20 alkyl, preferably cl-10 alkyl, more preferably cl-6 alkyl, 
most preferably Cu C2 or C3 alkyl, or aryl; -CN, -SH; 
-N02 ; -S-C1_20 alkyl, preferably C1 _10 alkyl, more pref-
erably C1 _6 alkyl, most preferably Cu C2 or C3 alkyl; -S-
ary!; aryl, -COOH; --COH; -COR or -COOR, where R 
is defined above; or --CONR12R13, wherein R12 and R13 are 
independently hydrogen or R as defined above; 
R1 and R2 are independently hydrogen, C1 _20 alkyl, prefer-
ably cl-10 alkyl, more preferably cl-6 alkyl, most preferably 
C1 , C2 or C3 alkyl; C1 _20 alkyl sulfonate, preferably C1_10 
alkyl sulfonate, more preferably C1_6 alkyl sulfonate, most 
preferably C1 , C2 , C3 , orC4 alkyl sulfate of sulfite; C1 _20 alkyl 
carboxylic acid or carboxylate, preferably C1 _10 alkyl car-
boxylic acid or carboxylate, more preferably C1 _6 alkyl car-
boxylic acid or carboxylate, most preferably C1 , C2 , C3 , or C4 
alkyl carboxylic acid or carboxylate; C1_20 alkyl amino, pref-
erably C1_10 alkyl amino or quatemized amino, more prefer-
ably C1_6 alkyl amino or quaternized amino, most preferably 
C1 , C2 , C3 , or C4 alkyl amino or quaternized amino; aryl, 
benzyl, oligoethylene glycol, or polyethylene glycol; and 
R3 and R4 are independently hydrogen; hydroxyl; ---ORs; 
-NH2 ; -NHR6 ; -NR7 Rs, C1 _20 alkyl, preferably C1_10 
alkyl, more preferably C1 _6 alkyl, most preferably Cu C2 or 
C3 alkyl; C1 _20 alkyl sulfonate, preferably C1 _10 alkyl sul-
fonate, more preferably C1_6 alkyl sulfonate, most preferably 
C1 , C2 , C3 , or C4 alkyl sulfonate; C1_20 alkyl carboxylic acid 
14 
R1 and R2 are independently hydrogen, C1_20 alkyl, prefer-
ably cl-10 alkyl, more preferably cl-6 alkyl, most preferably 
Cu C2 or C3 alkyl; C1 _20 alkyl sulfonate, preferably C1_10 
alkyl sulfonate, more preferably C1 _6 alkyl sulfonate, most 
5 preferably C1 , C2 , C3 , or C4 alkyl sulfonate; C1 _20 alkyl car-
boxylic acid or carboxylate, preferably C1 _10 alkyl carboxylic 
acid or carboxylate, more preferably C1 _6 alkyl carboxylic 
acid or carboxylate, most preferably C1 , C2 , C3 , or C4 alkyl 
carboxylic acid or carboxylate; C1_20 alkyl amino or quater-
lO nized amino, preferably C1 _10 alkyl amino or quatemized 
amino, more preferably C1 _6 alkyl amino or quatemized 
amino, most preferably C1 , C2 , C3 , or C4 alkyl amino or 
quatemized amino; aryl, benzyl, oligoethylene glycol, or 
15 
polyethylene glycol; and 
R3 and R4 are independently hydrogen; hydroxyl; ---ORs; 
-NH2 ; -NHR6 ; -NR7 Rs, C1 _20 alkyl, preferably C1_10 
alkyl, more preferably C1 _6 alkyl, most preferably C1 , C2 or 
C3 alkyl; C1 _20 alkyl sulfonate, preferably C1 _10 alkyl sul-
20 fonate, more preferably C1 _6 alkyl sulfonate, most preferably 
Cu C2 , C3 , or C4 alkyl sulfonate; C1 _20 alkyl carboxylic acid 
or carboxylate, preferably C1 _10 alkyl carboxylic acid or car-
boxylate, more preferably C1_6 alkyl carboxylic acid or car-
boxylate, most preferably Cu C2 , C3 , or C4 alkyl carboxylic 
25 
acid or carboxylate; C1_20 alkyl amino or quatemized amino, 
preferably C1_10 alkyl amino or quatemized amino, more 
preferably C1 _6 alkyl amino or quaternized amino, most pref-
erably C1 , C2 , C3 , or C4 alkyl amino or quatemized amino; 
-COOR; -Co2-, or -S03 -; wherein Rs-Rs are the same 
30 
as R; oligoethylene glycol, or polyethylene glycol; 
R11 isHorD; 
q is 0, 1, or 2; 
n is an integer from 1-5; and 
or carboxylate, preferably C1 _10 alkyl carboxylic acid or car-
boxylate, more preferably C1_6 alkyl carboxylic acid or car-
boxylate, most preferably Cu C2 , C3 , or C4 alkyl carboxylic 
35 
acid or carboxylate; C1_20 alkyl amino or quatemized amino, 
preferably C1_10 alkyl amino or quatemized amino, more 
preferably C1 _6 alkyl amino or quaternized amino, most pref-
erably Cu C2 , C3 , or C4 alkyl amino or quatemized amino; 
-COOH; -Co2-; or -S03 -; wherein Rs-Rs are the same 
40 
as R; oligoethylene glycol, or polyethylene glycol; 
the benzene ring represented by dotted lines is optional; 
(h) 
R11 is Hor D; and 
n is an integer from 1-5. 
(g) 
x 
)q 
\ ___ / 
wherein x is hydrogen; halogen; cl-20 alkyl, preferably 
cl-10 alkyl, more preferably cl-6 alkyl, most preferably cl, 
C2 or C3 alkyl; aryl; -OR, where R is C1 _20 alkyl, preferably 
C1 _10 alkyl, more preferably C1 _6 alkyl, or aryl; hydroxyl; 
-NRsR6 , where Rs and R6 are independently hydrogen, 
cl-20 alkyl, preferably cl-10 alkyl, more preferably cl-6 alkyl, 
most preferably Cu C2 or C3 alkyl, or aryl; -CN, -SH; 
-N02 ; -S-C1_20 alkyl, preferably C1 _10 alkyl, more pref-
erably C1 _6 alkyl, most preferably Cu C2 or C3 alkyl; -S-
ary!; aryl, -COOH; --COH; -COR or -COOR, where R 
is defined above; or --CONR12R13, wherein R12 and R13 are 
independently hydrogen or R as defined above; 
45 
wherein x is hydrogen; halogen; cl-20 alkyl, preferably 
cl-10 alkyl, more preferably cl-6 alkyl, most preferably cl, 
C2 or C3 alkyl; aryl; -OR, where R is C1 _20 alkyl, preferably 
C1_10 alkyl, more preferably C1 _6 alkyl, or aryl; hydroxyl; 
50 -NRsR6 , where Rs and R6 are independently hydrogen, 
cl-20 alkyl, preferably cl-10 alkyl, more preferably cl-6 alkyl, 
most preferably C1 , C2 or C3 alkyl, or aryl; -CN, -SH; 
-N02 ; -S--C1 _20 alkyl, preferably C1 _10 alkyl, more pref-
erably C1 _6 alkyl, most preferably C1 , C2 or C3 alkyl; -S-
55 aryl; aryl, -COOH; --COH; -COR or -COOR, where R 
is defined above; or 
--CONR12R13, wherein R12 and R13 are independently 
hydrogen or R as defined above; 
R1 and R2 are independently hydrogen, C1_20 alkyl, prefer-
60 ably cl-10 alkyl, more preferably cl-6 alkyl, most preferably 
Cu C2 or C3 alkyl; C1 _20 alkyl sulfonate, preferably C1_10 
alkyl sulfonate, more preferably C1 _6 alkyl sulfonate, most 
preferably C1 , C2 , C3 , or C4 alkyl sulfonate; C1 _20 alkyl car-
boxylic acid or carboxylate, preferably C1 _10 alkyl carboxylic 
65 acid or carboxylate, more preferably C1 _6 alkyl carboxylic 
acid or carboxylate, most preferably C1 , C2 , C3 , or C4 alkyl 
carboxylic acid or carboxylate; C1_20 alkyl amino or quater-
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nized amino, preferably C1 _10 alkyl amino or quatemized 
amino, more preferably C1 _6 alkyl amino or quatemized 
amino, most preferably C1 , C2 , C3 , or C4 alkyl amino or 
quaternized amino; aryl, benzyl, oligoethylene glycol, or 
polyethylene glycol; and 
R3 and R4 are independently hydrogen; hydroxyl; ---ORs; 
-NH2 ; -NHR6 ; -NR7 Rs, C1 _20 alkyl, preferably C1_10 
alkyl, more preferably cl-6 alkyl, most preferably c1' c2 or 
C3 alkyl; C1 _20 alkyl sulfonate, preferably C1 _10 alkyl sul-
fonate, more preferably C1_6 alkyl sulfonate, most preferably 
C1 , C2 , C3 , or C4 alkyl sulfonate; C1_20 alkyl carboxylic acid 
16 
fonate, more preferably C1 _6 alkyl sulfonate, most preferably 
Cv C2 , C3 , or C4 alkyl sulfonate; C1 _20 alkyl carboxylic acid 
or carboxylate, preferably C1 _10 alkyl carboxylic acid or car-
boxylate, more preferably C1_6 alkyl carboxylic acid or car-
5 boxylate, most preferably Cv C2 , C3 , or C4 alkyl carboxylic 
acid or carboxylate; C1_20 alkyl amino or quatemized amino, 
preferably C1_10 alkyl amino or quatemized amino, more 
preferably C1 _6 alkyl amino or quaternized amino, most pref-
erably C1 , C2 , C3 , or C4 alkyl amino or quatemized amino; 10 
--COOR; -Co2-; or -S03 -; wherein Rs-Rs are the same 
as R; oligoethylene glycol, or polyethylene glycol; 
Y and Z are independently carbon, nitrogen or sulfur, 
wherein ifY and/or Z is carbon, the carbon will be tetravalent 
having two substituents as defined above; ifY and/or Z is 
15 sulfur; the sulfur will be divalent; and ifY and/or Z is nitro-
gen, the nitrogen will be trivalent, having one substituent as 
defined above; 
or carboxylate, preferably C1 _10 alkyl carboxylic acid or car-
boxylate, more preferably C1_6 alkyl carboxylic acid or car-
boxylate, most preferably Cv C2 , C3 , or C4 alkyl carboxylic 
acid or carboxylate; C1_20 alkyl amino or quatemized amino, 
preferably C1_10 alkyl amino or quatemized amino, more 
preferably C1 _6 alkyl amino or quaternized amino, most pref-
erably Cv C2 , C3 , or C4 alkyl amino or quatemized amino; 
-COOH; -Co2-; or -S03 -; wherein Rs-Rs are the same 20 
as R; 
R12 is H or D; and 
the benzene ring represented by dotted lines is optional; 
R11 is Hor D; and 
n is an integer from 1-5. 
(i) 
, ....... -.......... 
wherein x is hydrogen; halogen; cl-20 alkyl, preferably 
cl-10 alkyl, more preferably cl-6 alkyl, most preferably cl, 
C2 or C3 alkyl; aryl; -OR, where R is C1 _20 alkyl, preferably 
C1 _10 alkyl, more preferably C1 _6 alkyl, or aryl; hydroxyl; 
-NRsR6 , where Rs and R6 are independently hydrogen, 
cl-20 alkyl, preferably cl-10 alkyl, more preferably cl-6 alkyl, 
most preferably Cv C2 or C3 alkyl, or aryl; -CN, -SH; 
N02 ; -S---C1 _20 alkyl, preferably C1 _10 alkyl, more prefer-
ably C1 _6 alkyl, most preferably Cv C2 or C3 alkyl; -S-aryl; 
aryl, --COOR; ---COH; -COR or --COOR, where R is 
defined above; or ---CONR13R14, wherein R13 and R14 are 
independently hydrogen or R as defined above; 
R1 -R4 are independently hydrogen, C1 _20 alkyl, preferably 
cl-10 alkyl, more preferably cl-6 alkyl, most preferably cl, 
C2 or C3 alkyl; C1 _20 alkyl sulfonate, preferably C1_10 alkyl 
sulfonate, more preferably C1 _6 alkyl sulfonate, most prefer-
ably Cv C2 , C3 , or C4 alkyl sulfonate; C1_20 alkyl carboxylic 
acid or carboxylate, preferably C1_10 alkyl carboxylic acid or 
carboxylate, more preferably C1 _6 alkyl carboxylic acid or 
carboxylate, most preferably Cv C2 , C3 , or C4 alkyl carboxy-
lic acid or carboxylate; C1 _20 alkyl amino or quatemized 
amino, preferably C1_10 alkyl amino or quaternized amino, 
more preferably C1 _6 alkyl amino or quaternized amino, most 
preferably Cv C2 , C3 , or C4 alkyl amino or quatemized 
amino; aryl, benzyl, oligoethylene glycol, or polyethylene 
glycol; 
Rs and R6 are independently hydrogen; hydroxyl; ---ORs; 
-NH2 ; -NHR6 ; -NR7 Rs, C1 _20 alkyl, preferably C1_10 
alkyl, more preferably C1 _6 alkyl, most preferably Cv C2 or 
C3 alkyl; C1 _20 alkyl sulfonate, preferably C1 _10 alkyl sul-
30 
wherein x is hydrogen; halogen; cl-20 alkyl, preferably 
cl-10 alkyl, more preferably cl-6 alkyl, most preferably cl, 
C2 or C3 alkyl; aryl; -OR, where R is C1 _20 alkyl, preferably 
35 C1_10 alkyl, more preferably C1 _6 alkyl, or aryl; hydroxyl; 
-NRsR6 , where Rs and R6 are independently hydrogen, 
cl-20 alkyl, preferably cl-10 alkyl, more preferably cl-6 alkyl, 
most preferably C1 , C2 or C3 alkyl, or aryl; -CN, -SH; 
-N02 ; -S---C1 _20 alkyl, preferably C1 _10 alkyl, more pref-
40 erably C1 _6 alkyl, most preferably C1 , C2 or C3 alkyl; -S-
ary!; aryl, -COOH; ---COH; -COR or --COOR, where R 
is defined above; or -CONR13R14, wherein R13 and R14 are 
independently hydrogen or R as defined above; 
R1 and R2 are independently hydrogen, C1_20 alkyl, prefer-
45 ably cl-10 alkyl, more preferably cl-6 alkyl, most preferably 
Cv C2 or C3 alkyl; C1 _20 alkyl sulfonate, preferably C1_10 
alkyl sulfonate, more preferably C1 _6 alkyl sulfonate, most 
preferably C1 , C2 , C3 , or C4 alkyl sulfonate; C1 _20 alkyl car-
boxylic acid or carboxylate, preferably C1 _10 alkyl carboxylic 
50 acid or carboxylate, more preferably C1 _6 alkyl carboxylic 
acid or carboxylate, most preferably C1 , C2 , C3 , or C4 alkyl 
carboxylic acid or carboxylate; C1_20 alkyl amino or quater-
nized amino, preferably C1 _10 alkyl amino or quatemized 
amino, more preferably C1 _6 alkyl amino or quatemized 
55 amino, most preferably C1 , C2 , C3 , or C4 alkyl amino or 
quatemized amino; aryl, benzyl, oligoethylene glycol, or 
polyethylene glycol; 
R3 and R1 are independently hydrogen; hydroxyl; ---ORs; 
-NH2 ; -NHR6 ; -NR7 Rs, C1 _20 alkyl, preferably C1_10 
60 alkyl, more preferably C1 _6 alkyl, most preferably C1 , C2 or 
C3 alkyl; C1 _20 alkyl sulfonate, preferably C1 _10 alkyl sul-
fonate, more preferably C1 _6 alkyl sulfonate, most preferably 
Cv C2 , C3 , or C4 alkyl sulfonate; C1 _20 alkyl carboxylic acid 
or carboxylate, preferably C1 _10 alkyl carboxylic acid or car-
65 boxylate, more preferably C1_6 alkyl carboxylic acid or car-
boxylate, most preferably Cv C2 , C3 , or C4 alkyl carboxylic 
acid or carboxylate; C1_20 alkyl amino or quatemized amino, 
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preferably C1_10 alkyl amino or quatemized amino, more 
preferably C1 _6 alkyl amino or quaternized amino, most pref-
erably Cu C2 , C3 , or C4 alkyl amino or quatemized amino; 
-COOH; -Co2-; or -S03 -; wherein R5 -R8 are the same 
as R; oligoethylene glycol, or polyethylene glycol; 
Z is carbon, nitrogen, sulfur, or oxygen, wherein ifY and/or 
Z is carbon, the carbon will be tetravalent having two sub-
stituents as defined above; if Y and/or Z is sulfur and/or 
oxygen; the sulfur and/or oxygen will be divalent; and ifY 
10 
and/or Z is nitrogen, the nitrogen will be trivalent, having one 
substituent as defined above; 
R12 is H or D; and 
the benzene ring represented by dotted lines is optional; 
In a preferred embodiment, the reduced cyanine dye is 15 
selected from Hydro-IR-676, Hydro-Cy3, Hydro-Cy5, 
Hydro-Cy7, Hydro-IR-783, Hydro-ICG, deuterated deriva-
tives thereof, and combinations thereof. The structures of the 
hydrocyanine dyes are shown below: 
20 
30 
Hydro-IR-676 
18 
-continued 
Hydro-Cy5 
Hydro-Cy7 
Hydro-IR-783 
The structures of the corresponding deuterocyanine dyes 
are shown below. Oxidation of deuterocyanines generates the 
identical cyanine dye as their hydrogen analogues, allowing 
these probes to be used with existing protocols for ROS 
35 sensors. 
# 
40 
Hydro-Cy5 
# 
45 
D-IR-676 
50 
# # N # N \ I (CH2)4S03Na 
(CH2)4S03Na 
Hydro-I CG 55 D-Cy5 
60 
65 
Hydro-Cy3 D-ICG 
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-continued 
20 
in the near infra-red) should allow it to detect ROS in vivo. 
This an important feature of these dyes, since most fluores-
cent dyes are not effective in vivo. 
As discussed in the Examples, hydrocyanines can detect at 
least nanomolar levels of ROS and emit in the near IR range 
(760-830 nm) in the case ofHydro-Cy7, Hydro-IR-783, and 
Hydro-ICG and their deuterated derivatives. At these emis-
sion wavelengths, in vivo, at a depth of0.5 cm, a 2-3 order of 
D-Cy3 10 magnitude reduction in sensitivity is anticipated, due to tissue 
attenuation and background fluorescence. The carotid artery 
is a superficial anatomic structure, which is located less than 
0.5 cm from the skin surface. Therefore, the hydrocyanines 
described herein should be able to detect a target analyte, 
15 which is at micromolar concentrations, at least 0.5 cm from 
the skin surface. Moreover, many of the hydrocyanines 
described herein accumulate within cells after reaction with 
ROS, which may result in amplification of the signal due to 
D-Cy5 20 
multiples injections. 
Charged and membrane impermeable molecules, such as 
Hydro-ICG, are suitable for measuring extracellular ROS 
production. The photochemical properties of exemplary dyes 
are shown in Table 3. 
25 As discussed above, the hydrocyanines can also be unsym-
metrical hydrocyanines, wherein the end groups are chemi-
cally different. The differences can include differences in the 
ring structure of the end group and/or unsymmetrical substi-
tution of the end groups. For example, suitable unsymmetri-
D-Cy7 
30 cal dyes include dues containing any two of the end groups 
shown in structures a-j. Exemplary unsymmetrical dyes are 
shown below: 
35 
40 
D-IR-783 
The reduced dyes described herein possess excellent sta-
bility to auto-oxidation, have tunable emission wavelengths, 45 
and picomolar to millimolar sensitivity. In one embodiment, 
the reduced dyes have at least picomolar to millimolar sensi-
tivity. In a preferred embodiment, the reduced dyes have at 
least nanomolar (e.g., 1-50 nM, preferably 1-30 nM, more 
preferably 5-30 nM) to millimolar sensitivity to ROS. For 50 
example, the cyanine dyes described herein have emission 
wavelengths from 500-1100 nm (into the near infra-red), 
which is significantly higher than DHE or sulfonate ester-
based dyes, and thus have potential for in vivo applications. 
The reduced dyes can be used to image ROS, such as hydrox- 55 
ide radical and superoxide, in serum, cell cultures, tissue 
explants, and in vivo. 
Hydro-Cy3 is a membrane permeable molecule with the 
ability to diffuse into cells; however, after oxidation by intra-
cellular ROS, it is fluorescent and membrane impermeable. 60 
Therefore, oxidized Hydro-Cy3 should accumulate within 
cells over producing ROS and detect intracellular ROS pro-
duction. Hydro-Cy7 has properties suitable for measuring 
ROS in vivo. Hydro-Cy7 is also membrane permeable and 
should accumulate within cells and tissues that overproduce 65 
intracellular ROS. However, the high emission wavelength of 
oxidized Hydro-Cy7 O'-ex =735 nm and "-em =7 60 nm, which is 
U-HCy5 
OH 
U-HCy3_COOH 
The sensitivity and specificity of the unsymmetrical hydro-
cyanines were similar/comparable with their symmetrical 
counterparts. The sensitivity of U-HydroCy3-COOH was 
similar to Hydro-Cy3 and U-HydroCy5 was similar to 
Hydro-Cy5 (all have nano molar sensitivity towards hydroxyl 
radical and superoxide anion radical and are highly specific 
for radicals). 
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i. Reduced Cyanines Having Improved Water Solubility 
In one embodiment, the reduced cyanine is a hydrocyanine 
or deuterocyanine having improved water solubility. Hydro-
22 
B. Other Reduced Dyes 
As discussed above, any reduced dye can be used in the 
compositions and methods of making and using thereof 
described herein. In one embodiment, the reduced dye exhib-
its negligible fluorescence compared to the oxidized dye. In 
another embodiment, the reduced dye is membrane perme-
able and the oxidized dye is membrane impermeable. In yet 
another embodiment, the reduced dye and the oxidized dye 
cyanines deuterocyanines can be modified to contain water-
soluble functional groups which improve the water solubility 5 
of the dyes. Suitable functional groups include oligo- orpoly-
alkylene oxide, such as oligo- or polyethylene, sulfonate 
groups, alkyl sulfonate groups, phosphoric or phosphonic 
acid residues, zwitterionic groups, carboxylate groups, and 
alkyl carboxylate groups. In a preferred embodiment, the 
functional groups are oligo- or polyethylene glycol. The num-
ber of repeat units is from about 1 to about 1,000, preferably 
from about 1 to about 500, more preferably from about 1 to 
about 100. 
10 are membrane impermeable. 
The reduced dye can be a hydrodye (i.e., it-bond or bonds 
is reduced by hydrogen), a deuterodye (i.e., it-bond or bonds 
is reduced by deuterium), or a combinations thereof. Suitable 
it-bonds which can be reduced include, but are not limited to, 
15 iminium bonds (i.e., C=N bond), C=C bonds, C=S bonds, 
C=O bonds, and combinations thereof. These groups are typically attached to the end group, such 
1. Deuterated Leuco Dyes 
In one embodiment, the reduced dye is a deuterated leuco 
dye. As discussed above, DHE is inadequate as an ROS probe 
because of its poor stability due to auto-oxidation, particu-
as the indole ring system, particularly the indole nitrogen. 
However, functional groups which improve the water solu-
bility can be attached to the bridge and/or other parts of the 20 
dye, including other parts of the end group, such as an aro-
matic ring in a cyclic end group. In one embodiment, the 
functional groups, i.e., polyethylene glycol ("PEG") groups, 
are attached to the end groups of the cyanine dye, e.g., the 
indole ring system. 25 larly in aqueous solutions. Reducing ethydium bromide with 
sodium borodeuteride (NaBD4 ) quantitatively converts DHE 
to D-DHE. Replacing the benzylic hydrogen with deuterium 
increases the stability ofDHE by 4-6 fold, due to the primary 
kinetic isotope effect. This is shown in FIG. 2. FIG. 2a com-
An exemplary functionalized dye is shown below: 
wherein n=O, 1, 2, or 3 and mis from 1-1000. 
In another embodiment, the PEG groups are attached to 
both the nitrogen and the aromatic ring as shown below: 
HO~O~ ~ ~ ~ 
,,,;:::; N© N 
~ ~ 
0 0 
< < 
30 pares the stability of dihydroethydium (DHE) and deutero-
hydroethydium (D-DHE or DDE) in solution. FIG. 2b com-
pares the stability of solid DHE and D-DHE. The presence of 
deuterium in DHE makes the molecules less susceptible to air 
35 oxidation, resulting in increased stability. Therefore, D-DHE 
may be a suitable compound for the detection of ROS. Other 
suitable deuterated leuco dyes which can be used include, but 
are not limited to, deuterated rhodamine, deuterated 
40 rhodamine analogs (such as the deuterated analog shown 
below), deuterated carboxy-2'7'-dichlorofluorescein diac-
etate ( deuterated DCFDA), dideuterocalceinAM, dideuteror-
hodamine 6G, deuterolucigenin, deuteroRedoxSensor Red 
CC-1, deuterated 5-chloromethy 1-2'7'-diehlorofluorescein 
45 diacetate ( deuterated 5-CM-DCFDA), deuterated 6-chlorom-
ethyl-2'7'-dichlorofluorescein diacetate (deuterated 6-CM-
DCFDA), combinations thereof, and combinations with one 
or more reduced cyanines. 
~ ~O~OH 
~ m 
OH OH 
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Examples of these dyes are shown below: 
Deuterated DCFDA 
Deuterated Rhodamine 
Deuterated Rhodamine Analog 
Cl 
0 
OAMe 
As discussed above with respect to the cyanines, other 
reduced dyes can be modified with water soluble functional 
groups to improve the water-solubility of the dye. The nature 
of the functional group and/or its location can be readily 
determined by one of ordinary skill in the art based on the 
functional groups present on the dye and the chemistry used 
to attached the functional groups. 
III. Methods of Manufacture 
A. Reduced Cyanine Dyes 
Reduced dye can be prepared by reacting the oxidized dye 
with a suitable reducing agent. One of ordinary skill in the art 
can readily determine the appropriate reducing agent based 
on then-bond to be reduced. 
In one embodiment, reduced cyanine dyes can be prepared 
in a single step reaction by reacting the cyanine dye with a 
reducing agent to reduce the imine bond to the corresponding 
amine. A variety of reducing agents are known in the art. In 
one embodiment, the cyanine dye is reduced using sodium 
borohydride, NaBH4 . Sodium borohydride reduces alde-
hydes and ketones into alcohols, as well as the more reactive 
carboxylic acid derivatives acyl chlorides and thiol esters. 
However, unlike the more powerful reducing agent lithium 
aluminium hydride, sole use ofNaBH4 with gentle reaction 
conditions will not reduce esters, amides, or carboxylic acids. 
NaBH4 can also be used to reduce imine bonds to the corre-
sponding amine (L. Blackburn, R. J. K. Taylor, Org. Lett., 
2001, 3, 1637-1639). The deuterocyanines can be synthesized 
by reacting the corresponding cyanine dye with a deuterated 
10 
15 
20 
25 
30 
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reducing agent, such as sodium borodeuteride. The synthesis 
and mechanism of reduction of a cyanine dye and oxidation 
by ROS is shown in Scheme 1. 
Scheme 1. Reduction and Oxidation ofCyanine Dyes 
NaBJLi 
-
ROS 
-
IV. Methods of Use 
The compounds described herein can be used as diagnostic 
35 tools to detect and/or quantify ROS in a sample in vitro or to 
evaluate/detect a variety of diseases and disorders, or markers 
for diseases or disorders, characterized by the production or 
overproduction of ROS, in vivo. The fluorescence emitted by 
the oxidized dyes can be measured using fluorescence spec-
40 troscopy or fluorescence microscopy depending on the appli-
cation. Exemplary methods of fluorescence microscopy 
include, but are not limited to, confocal laser scanning 
microscopy, total internal reflection fluorescence micros-
copy, histological analysis via fluorescence, flow cytometry, 
45 analyses using plate readers, such as fluorescence mi crop late 
readers, standard or mini fluormeters, or epifluorescence 
microscopes. 
The general procedure for using the reduced dyes is as 
follows. One or more reduced dyes are administered in vivo 
50 or in vitro to contact cells, cell cultures, tissues, organs, 
serum, bodily fluids, etc. The one or more reduced dyes can be 
formulated with one or more carriers depending on the assay. 
The reduced dye(s) are incubated with the biological sample 
for a period of time sufficient for the reduced dye to react with 
55 reactive oxygen species present in the sample. After such 
time, the sample is analyzed for fluorescence intensity. The 
fluorescence intensity after incubation is compared to the 
fluorescence intensity of the reduced dye. An increase in the 
fluorescence intensity of the dye in the biological sample 
60 indicates oxidation of the dye, and thus presence of reactive 
oxygen species. The increased fluorescence can be measured/ 
detected using the techniques listed above. 
In Vivo Applications 
Diagnosis of Diseases and Disorders or Markers for Dis-
65 eases and Disorders In Vivo 
In general, up-regulation of reactive oxygen species 
reflects initiation of a disease or disease state. Therefore, the 
US 8,628,753 B2 
25 
more fluorescence observed after administration of the 
reduced dye, the higher the propensity for the disease or 
disease state. 
26 
Exemplary diseases and disorders include, but are not lim-
ited to, carotid artery injuries, atherosclerosis, hypertension, 
cancers, diseases and disorders characterized by inflamma-
tion, radiation-induced late normal tissue damage (Zhao et 
al., Curr. Med. Chem., 16(2), 130-43 (2009), tissue damages 
due to chemotherapy, reperfusion after ischemia, or trans-
plantation, diabetes, such as type 1 diabetes (TlD) (Chen et 10 
al., Ann. N. Y. A cad. Sci., 1150: 157066, December 2008), 
neurodegenerative diseases, such as Alzheimer's disease 
(Block, BMC Neurosci, 9 Suppl. 2:S8, December 2008), Par-
kinson's disease (Zhou et al., Ann. N. Y. Acad. Sci., 1147:93- 15 
104 December (2008)), ALA, and Huntington's disease 
(Stack et al., Ann. N. Y. Acad. Sci., 1147:79-92 December 
(2008)), cerebrovascular disease (Chrissobolis et al., Trends 
Mal. Med., 14(11), 495-502, November (2008)), cystic fibro-
Positron Emission Tomography (PET) Contrast Agents 
The hydrocyanines and/or deuterocyanines described 
herein can be used as PET contrast agents. For example, 
cyanine dyes can be radiolabeled with tritium or 11 C via 
alkylation using the corresponding labeled alkyl iodides. The 
labeled cyanine dye can be reduced using sodium borohy-
dride or sodium borodeuteride as described below to form the 
corresponding hydrocyanine or deuterocyanine suitable for 
imaging ROS. 
Imaging of Biomolecules In Vivo 
One of the benefits of the hydro- and/or deuterocyanines 
for imaging ROS is that they oxidize to form cyanine dyes, a 
family of dyes which possess excellent chemical and physical 
properties for in vivo fluorescence imaging. Cyanine dyes 
have been used extensively for imaging biomolecules in ani-
mal and humans because of their high emission wavelengths, 
high photostability, and high quantum yields. For example, 
Cy-5 conjugated to cell ligands can detect picomolar/nano-
molar levels of target analyte, in vivo, in superficial anatomic 
structures, such as tumors. The cyanine dye, indocyanine 
green (ICG), has been used in humans for imaging angiogen-
sis (Pongnimitprasert et al., Ann. Biol. Clin., 66(6), 621-9, 20 
November-December (2008)), chronic kidney disease and 
cardiovascular disease (Cachofeiro et al., Kidney Int. Suppl., esis in the eyes and has been investigated for breast cancer 
imaging in optical inherence tomography imaging. The use of 
Cy-5 and ICG for in vivo imaging demonstrates the biocom-
patibility of cyanine dyes (and thus the reduced cyanine 
dyes). 
11 l:S4-9, December (2008)), preeclampsia (Gilbert et al., 
Expert. Rev. Cardiovasc. Ther., 6(10), 1367-77, November 
(2008)), and ophthalmic diseases. The compounds described 25 
herein can also be used as contrast agents and as markers for 
imaging biomolecules in vivo, such as through photoacoustic 
imaging. 
As discussed above, one of the advantages of the reduced 
dyes is that, in the case ofhydrocyanines, the reduced mol-
ecules are membrane permeable and thus accumulate in cells Detection of ROS Production in Carotid Artery Injuries 
The overproduction of ROS in the carotid artery is patho-
logically linked to the growth and rupture of carotid artery 
atherosclerotic plaques, which cause strokes. Increased ROS 
production is necessary for the development of carotid artery 
atherosclerosis in mice, rat, and rabbit models. ROS has been 
implicated in many of the key pathological features of ath-
erosclerosis, such as endothelial dysfunction, angiogenesis, 
smooth muscle cell overgrowth, endothelial cell apoptosis, 
expression of inflannnatory proteins, vascular remodeling, 
and the activation ofMMPs, all of which have been associated 
with plaque ruptures. Contrast agents which can image ROS 
production in the carotid artery have the potential to diagnose 
active atherosclerotic lesions in the carotid artery and identify 
patients who are at risk of developing strokes. 
The rate of superoxide production in vivo in carotid arter-
ies, following vascular injury, has been measured in rats ex 
vivo at a rate of2-3 nmols/mg wet carotid tissue/minute and 
is increased by a factor of 2-3 in most animal models of 
carotid injury. This is an extremely high rate of ROS produc-
tion, corresponding to micromoles/mL wet carotid tissue/ 
minute and should be detectable by the hydrocyanines 
described herein, even after attenuation, in view of the results 
described in the Examples. 
As discussed in the Examples, hydrocyanines can detect 
nanomolar levels of ROS and emit in the near IR range (760-
830 nm) in the case of Hydro-Cy7, Hydro-IR-783, and 
Hydro-ICG and their deuterated derivatives. At these emis-
sion wavelengths, in vivo, at a depth of0.5 cm, a 2-3 order of 
magnitude reduction in sensitivity is anticipated, due to tissue 
attenuation and background fluorescence. The carotid artery 
is a superficial anatomic structure, which is located less than 
0.5 cm from the skin surface. Therefore, the hydrocyanines 
described herein should be able to detect a target analyte, 
which is at micromolar concentrations, 0.5 cm from the skin 
surface. Moreover, many of the hydrocyanines described 
herein accumulate within cells after reaction with ROS, 
which may result in amplification of the signal due to mul-
tiples injections. 
30 and tissue. Upon reaction with ROS, the reduced molecules 
oxidize to cyanine dyes resulting in a substantial increase in 
fluorescence. The oxidized cyanines are membrane imperme-
able and thus are trapped within the cells and tissue. The use 
of reduced dyes allows one to detect/image the overproduc-
35 ti on of ROS in specific cells and/or tissues. 
Photoacoustic Imaging 
Photoacoustic imaging is based on the photoacoustic 
effect. In photoacoustic imaging, non-ionizing laser pulses 
are delivered into biological tissues (when radio frequency 
40 pulses are used, the technology is referred to as thermoacous-
tic imaging). Some of the delivered energy will be absorbed 
and converted into heat, leading to transient thermoelastic 
expansion and thus wideband (e.g. MHz) ultrasonic emission. 
The generated ultrasonic waves are then detected by ultra-
45 sonic transducers to form images. It is known that optical 
absorption is closely associated with physiological proper-
ties, such as hemoglobin concentration and oxygen satura-
tion. As a result, the magnitude of the ultrasonic emission (i.e. 
photoacoustic signal), which is proportional to the local 
50 energy deposition, reveals physiologically specific optical 
absorption contrast. 2D or3D images of the targeted areas can 
then be formed. Reduced dyes, such as hydrocyanine or deu-
terocyanines, would be used for PA imaging in the identical 
way that they are used for fluorescent imaging. The dyes are 
55 injected directly on the potential diseased tissue, or given 
intravenously, and then imaged by photoacoustic imaging. 
Formulations for In Vivo Applications 
For in vivo applications, the formulations can be adminis-
tered by a variety of routes. Typically, the compounds are 
60 formulated for parenteral administration including, but not 
limited to, intravenous, intraarterial, intramuscular, intraperi-
toneal, subcutaneous, intradermal, infusion, subconjunctive, 
and intracatheter (e.g., aurologic delivery), as well as admin-
istration via external scopic techniques such as, for example, 
65 arthroscopic or endoscopic techniques. 
The amount of reduced dye is the minimum amount 
required to yield detectable signal in the sample within a 
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reasonable time, with minimal background fluorescence. The 
exact concentration of reduced dye to be used is dependent 
upon the experimental conditions and the desired results, and 
optimization of experimental conditions is typically required 
28 
upon the experimental conditions and the desired results, and 
optimization of experimental conditions is typically required 
to determine the best concentration of reduced to be used in a 
given application. The concentration of reduced dye typically 
ranges from nanomolar to millimolar, preferably from nano-
molar to micromolar. The reduced dye concentrations are 
readily determined from methods known in the art for use of 
similar compounds under comparable conditions for the 
desired optical response. Typically, the concentration of the 
to determine the best concentration of reduced to be used in a 
given application. The concentration of reduced dye typically 
ranges from nanomolar to millimolar, preferably from nano-
molar to micromolar. The reduced dye concentrations are 
readily determined from methods known in the art for use of 
similar compounds under comparable conditions for the 
desired optical response. In one embodiment, the amount of 
dye is from about 50 µg/kg to about 50 g/kg, preferably from 
about 50 µg/kg to about 10 g/kg, more preferably from about 
50 µg/kg to about 1 g/kg, most preferably from about 50 µg/kg 
to about 0.1 g/kg. 
10 dye contacted with the cells is from about 1 µM to about 100 
µM. However, the specific concentration can be readily deter-
mined based on the assay being performed. In general, the 
compounds described herein will be dissolved or suspended 
in an appropriate solvent suitable for the intended application. 
15 Suitable solvents include aqueous solvents, such as water, 
PBS, saline; organic solvents, such as DMSO and alcohols, 
and combinations thereof. The dyes can be encapsulated in 
various nanostructures to improve cell delivery. Suitable 
nanostructures include, but are not limited to, liposomes, 
The compounds will typically be combined with one or 
more excipients, additives, or carriers. As used herein, the 
"carrier" is all components present in the pharmaceutical 
formulation other than the reduced dyes. The term "carrier" 
includes, but is not limited to, solvents, suspending agents, 
dispersants, buffers, pH modifying agents, isotonicity modi-
fying agents, preservatives, antimicrobial agents, and combi-
nations thereof. Other additives include those useful for pro-
cessing or preparation of the composition, can aid in the 
incorporation or stability of the compositions, or can be use- 25 
ful in modifying performance of the composition. 
20 microparticles, such as polymeric microparticles, and 
micelles, such as polymeric micelles formed from block 
copolymers. 
The compositions can contain other excipients including 
any number of other medically or pharmaceutically accept-
able agents such as preservatives, lipids, fatty acids, waxes, 
surfactants, plasticizers, porosigens, antioxidants, bulking 30 
agents, buffering agents, chelating agents, cosolvents, water-
soluble agents, insoluble agents, metal cations, anions, salts, 
osmotic agents, synthetic polymers, biological polymers, 
hydrophilic polymers, polysaccharides, sugars, hydrophobic 
polymers, hydrophilic polymers, and combinations thereof. 35 
The compositions can be administered to specific locations 
(e.g., local delivery) including, but not limited to, intrathecal, 
intracardiac, intraosseous (bone marrow), stereotactic-
guided delivery, infusion delivery, CNS delivery, stereo-tac-
tically administered delivery, orthopaedic delivery (for 40 
example, delivery to joints, into bone and/or bone defects, 
cardiovascular, inter- and intra- and para-ocular (including 
intravitreal and scleral and retrobulbar and sub-tenons deliv-
ery), as well as delivery to any multitude of other sites, loca-
tions, organs, etc. 45 
In Vitro and Ex Vivo Applications 
V. Kits 
The term "kit" as used refers to a packaged set of related 
components, typically one or more compounds or composi-
tions. The kit include one or more reduced dyes, one or more 
carriers suitable for in vitro and/or in vivo applications, and 
one or more containers to store the one or more reduced dyes 
and/or one or more carriers, such as solvents, buffers, stabi-
lizers, pH adjusting agents, etc. The kit optionally contains 
instructions for how to prepare the one or more reduced dyes, 
or a composition containing the one or more reduced dye, 
how to administer the dye or composition containing the dye, 
and how to detect oxidation of the dye (e.g., excitation wave-
length and emission wavelength). In a preferred embodiment, 
the kit contains instructions for performing an assay that 
detects the presence of one or more reactive oxygen species. 
The kit may further contain one or more pieces of equipment 
to administer the dye, or composition containing the dye 
including, but not limited to, syringes, pipettes, pipette bulbs, 
spatulas, vials, syringe needles, and combinations thereof. 
EXAMPLES 
Example 1 
Representative Procedure for the Synthesis of 
Hydrocyanines 
Cy3 (100 mg, 0.2 mmol) was dissolved in 5 ml of metha-
nol. The mixture was placed in a 4-drum vial covered with 
aluminum foil. Sodium borohydride, NaBH4 (3 mg, 0.08 
The reduced dyes, and compositions contammg the 
reduced dyes, can be used for a variety of in vitro and/or ex 
viva assays. The dye can be used for single cell imaging or to 
assay a cell suspension. For example, the dye can be loaded 50 
into cells by incubating the dye(s) with the cells for a suffi-
cient period of time, for example, 20 minutes. Specific assays 
include live organ cultures as well as cell cultures assays in 
which DHE is used. DHE has been used for detection of 
oxidative activities in viable cells, including respiratory burst 55 mmol in 0.5 ml methanol), was added dropwise to the purple 
Cy3 solution. After the addition of NaBH4 , the mixture was 
stirred for 10 minutes, generating a colorless solution. The 
reaction mixture was stirred an additional 10 minutes before 
removing the solvent under reduced pressure. The resulting 
in phagocytes, superoxide generation in mitochondria or as a 
vital stain in flow cytometry for imaging and analysis ofintact 
cells. It has also been shown to exhibit increased fluorescence 
in various models of apoptosis. DHE can be used as a generic 
substrate for the fluorimetric detection of oxidases, such as 
peroxidase; for the detection of cytochromes; and for the 
detection of free radical production in brain tissue. 
Formulations for In Vitro and Ex Vivo Applications 
The reduced dyes described herein are typically solids at 
room temperature. Therefore, the compounds will generally 
be dissolved or suspended in carrier for administration. The 
exact concentration of reduced dye to be used is dependent 
60 solid was dissolved in 10 ml of dichloromethane (CH2 Cl2 ) 
and 5 ml water and vigorously shaken. The organic layer was 
extracted with additional dichloromethane (5 mlx2), dried 
over anhydrous sodium sulfate, and the solvent was removed 
under reduced pressure. The reduced dye was used without 
65 additional purification. 
Reduced versions of Cy5, IR-676, Cy7, and ICG were 
prepared using the procedure described above, or a modified 
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version thereof. The reduction of the imine was confirmed by 
1 H and 13C NMR. A summary of the yields of the various 
reduced cyanines is shown in Table 1. 
TABLE I-continued 
Isolated yields of various hydrocyanines 
TABLE 1 
Isolated yields of various hydrocyanines 
Hydrocyanine 
Hydro-Cy3 
Hydro-Cy5 
Hydro-IR-676 
Hydro-Cy7 
Isolated Yield (%) 
97 
95 
93 
95 
Hydrocyanine 
Hydro-IR-783 
Hydro-ICG 
Isolated Yield(%) 
93 
93 
The hydrocyanines exhibited negligible fluorescence due 
10 to reduction of the iminium cation which results in the dis-
ruption of the it-conjugation. 
Deuterocyanines were prepared using the produced above 
except sodium borohydride was replaced with sodium boro-
deuteride. Deuterorhodamine was prepared in a similar man-
ner. A comparison of the stability of the hydrocyanines and 
their deuterated counterparts is shown in Table 2. 
TABLE2 
Deuteration increases the stability to aerial-oxidation of superoxide and radical oxidant probes 
Oxidized Forms 
1-5 
N 
I 
Et 
Cy3 (3) 
,,,? 
N 
I 
Me 
Cy5 (4) 
# # 
N 
I 
Me 
Cy7 (5) 
Rhodamine (6) 
~ 
,,,? 
~ 
# 
Reduced Forms 
6-10 (HID) 
Hydro-Cy3 (7H) 
Deutero-Cy3 (7D) 
,,,? 
Hydro-Cy5 (SH) 
Deutero-Cy5 (SD) 
# # 
Hydro-Cy7 (9H) 
Deutero-Cy7 (9D) 
MeOOC 
Hydrorhodamine (!OH) 
Deuterorhodamine (1 OD) 
Yield T112 
x [%]" [h] kJ!kn 
H 97 36 3.7 
D 96 S4 
N 
I 
Et 
H 95 31 4.1 
D 95 so 
N 
I 
Me 
H 95 30 4.6 
D 94 S2 
H 93 1.5 2.1 
D 93 2.1 
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Example 2 
Sensitivity of Reduced Dyes to Reactive Oxygen 
Species In Vitro 
Hydroxide Radical 
32 
This measurement was carried out using 100 µM of Hydro-
ICG at 25° C. The hydroxide radical was generated using the 
procedure described above. This demonstrates that hydrocya-
nines can compete effectively with biomolecules, such as 
protein thiols, for ROS. 
Hydroxide radicals were generated in situ by reacting 
hydrogen peroxide with Fe2 +. Various quantities of hydrogen 
peroxide (H2 0 2 ) stock solutions were added to a solution of 
hydrocyanine in methanol to generate hydrogen peroxide 
concentrations from about 2 to about 30 nM. Aqueous Fe2+(1 
µM) was added to the reduced dye/H20 2 solution to generate 
The sensitivity of deuterohydroethydium (D-DHE or 
DDE) was evaluated in the same manner. A 50 µM solution of 
DHE or D-DHE (DDE) in PBS buffer was treated with Fen-
ton's reagent (using 1-60 nM H2 0 2 with Fe2 +) and the fluo-
lO rescence of the oxidized product was measured. The results 
are shown in FIG. 4. FIG. 4 demonstrates that D-DHE can 
a 200 nM concentration. The resulting solution was kept at 
ambient temperature for 5 minutes and the fluorescence 15 
intensity was measured (11.eJ"-em) against a reagent blank 
(control solution containing only reagent) simultaneously. 
Superoxide 
Superoxide (02 -) was created by the enzymatic reaction of 
XAIXO (10 lm/10 mU) at 25° C. for 5 min (XA=Xanthene, 20 
XO=Xanthene oxidase). XA/XO (10 lm/10 mU) was added 
to buffered solutions ofHydro-Cy3 (10 mM) maintained in a 
3 7° C. water bath. The fluorescence emission of each reaction 
mixture was measured at 5-min intervals against a reagent 
blank using a fluorescence spectrometer. In some cases solid 25 
K02 (1 mg) or K02 dissolved in DMSO was added to a 
Hydro-IR-786 solution in methanol or DMSO and the emis-
sion spectra was recorded. Alternatively, hydro-IR-786 (2 
mg) was dissolved in 1 mL of ethanol and 50 µL of 2.0 mM 
K02 solution (7 mg K02 was dissolved in 10 mL dimethyl- 30 
sulfoxide) was added and stirred for 15 min before recording 
the emission spectra. 
accurately measure ROS in the concentration range of 5-60 
nM, having a linear relationship between fluorescence inten-
sity and hydrogen peroxide concentration in the Fenton's 
reagent (r=0.97). In contrast, DHE was incapable of accu-
rately detecting ROS in this concentration range and had an 
?-value of 0.79. Moreover, the average percent standard 
deviation of D-DHE was significantly smaller than that of 
DHE, which will improve the relative efficacy ofD-DHE. 
Example 3 
Specificity of Hydro-Cy7 to ROS 
A 50 µm Hydro-Cy7 solution was prepared in phosphate 
buffered saline (PBS) containing 1 % methanol. Various reac-
tive oxygen species were added to the 50 µm Hydro-Cy7 
solution, at an equimolar ratio to Hydro-Cy7, and the fluo-
rescence intensity was recorded after incubating 5 minutes at 
25° C. Superoxide (02 -) was added as solid K02 . Stock 
solutions of hydrogen peroxide, t-butyl hydrogen peroxide 
(TBHP), hypochlorite, 3-morpholinosydnonimine (SIN-1), 
glutathione (GSH), and 1,4-hydroquinone were prepared and 
A summary of the photochemical properties of various 
hydrocyanines, after reaction with superoxide, is shown in 
Table 3. 
TABLE3 
Swnmary of photochemical properties of various hydrocyanines 
35 added to the Hydro-Cy7 solution to generate a final concen-
tration of 50 µM. 3-(aminopropyl)-1-hydroxy-3-isopropyl-2-
oxo-l-triazene (NOC-5, 1 mM) was prepared as a 10 mM 
sodium hydroxide solution and added to the Hydro-Cy7 solu-
Fold Increase in 
Hydrocyanine Intensitya 
Hydro-Cy3 118 
Hydro-Cy5 97 
Hydro-IR-676 100 
Hydro-Cy7 104 
Hydro-IR-783 83 
Hydro-I CG 86 
'-eIAem nmb 
535/560 
635/660 
675/693 
735/760 
765/800 
750/830 
40 
45 
tion to generate a final concentration of 50 µM. The hydroxide 
and butoxy radicals were generated in situ by reacting hydro-
gen peroxide and t-butylperoxide with Fe2+. A 50 µM Hydro-
Cy7 solution, in PBS, containing 500 µM Fe2 + was prepared 
and either hydrogen peroxide or t-butyl hydrogen peroxide 
was added to this solution to generate a final concentration of 
50µM. 
Hydro-Cy7 exhibited specificity for superoxide and 
hydroxyl radical compared to other reactive oxygen species 
found in cells. FIG. 5 shows the ROS specificity for hydro-
Cy7. Hydro-Cy7 can detect superoxide, hydroxyl radical, and 
aFold increase was calculated by dividing the fluorescent intensity of oxidized hydrocyanine 
with the hydrocyanine fluorescence intensity. Concentrations ofhydrocyanines and oxidized 
hydrocyanines were 7.5 µMin 1 mL methanol. Hydrocyanines were oxidized with 20 µL of 
DMSO containing 20 mM K02 . 
hr:xcitation and emission wavelengths for the corresponding oxidized products 
The hydrocyanines exhibited negligible fluorescence due 
50 butoxy radical and has some sensitivity to hydrogen peroxide 
and reactive nitrogen species (ONoo-). A similar specificity 
profile was observed for Hydro-Cy3. 
to reduction of the iminium cations. However, after reaction 
with either superoxide or hydroxyl radical, the various hydro-
cyanines fluoresced at 560 nm, 660 nm, 760 nm, 800 nm, and 55 
830 nm, respectively (see Table 2). 
Hydro-Cy3 and Hydro-Cy7 exhibited nanomolar sensitiv-
ity toward hydroxyl radical in vitro having linear relation-
ships (r2=0.99) between fluorescence intensity and the 
hydroxyl radical in the 1-50 nM range (see FIG. 3a). For 60 
example, Hydro-Cy3 detected 5 nM concentration of hydrox-
ide radical, and generated a linear concentration curve against 
hydroxide radical in the concentration range of 5-50 nM 
hydroxide radical. This is significantly better than dihydroet-
hydium (DHE), which had an r2 -value of0.36 in this concen- 65 
tration range (see FIG. 3a). Hydro-ICG can detect ROS in 
100% human serum withnanomolar sensitivity (see FIG. 3b ). 
Example 4 
Stability of Reduced Dyes to Autooxidation 
A solution of hydrocyanine in PBS buffer (pH 7.4) was 
placed in anEppendorftube and placed in a 37° C. water bath. 
Stability was measured by monitoring the formation of the 
oxidation product using fluorescence spectroscopy over a 24 
hour period. The excitation and emission wavelengths for the 
hydrocyanines prepared in Example 1 are shown in Table 2. 
The excitation and emission wavelengths for DHE were 515 
and 590 nm. The results are shown in FIG. 6. Hydro-Cy3 and 
Hydro-Cy7 have a half-life of approximately 3 days in aque-
ous pH 7.4 buffer compared to DHE, which has a half-life of 
US 8,628,753 B2 
33 
only 30 minutes; a difference of two orders of magnitude. 
Similar results were obtained with Hydro-Cy5. 
The stability of deuterocyanines was evaluated in the same 
manner. Reducing ethydium bromide with sodium borodeu-
teride (NaBD4 ) quantitatively converts DHE to D-DHE. 5 
Replacing the benzylic hydrogen by deuterium increases the 
stability of DHE by 4-6 fold, due to the primary kinetic 
isotope effect. This is shown in FIG. 2. FIG. 2a compares the 
stability of dihydroethydium (DHE) and deuterohydroethy-
dium (D-DHE or DDE) in solution. FIG. 2b compares the 10 
stability of solid DHE and D-DHE. The presence of deute-
rium in DHE makes the molecules less susceptible to air 
oxidation, resulting in increased stability. 
34 
naling was evaluated using fluorescence spectroscopy. A 
comparative cell-culture study between DHE and D-DHE 
was conducted to evaluate the ability ofDHE and D-DHE to 
detect ROS production in rat aortic smooth muscle (RASM) 
cells, during angiotensin (Ang) II mediated cell signaling. 
RASM cells were isolated as described above, stimulated 
with Ang II and then incubated with 10 µM of either D-D HE 
or DHE for 10 minutes and imaged by fluorescent micros-
copy. DDE was significantly better than DHE at detecting 
intracellular ROS produced during cell signaling. For 
example, RASM cells incubated with DHE generated a large 
amount of background fluorescence, presumably due to the 
high auto-oxidation rate ofDHE. Stimulation of RAS Ms with 
Example 5 
Detection of ROS by Reduced Dyes in Rat Aortic 
Smooth Muscle (RASM) Cells 
15 Ang II was not detected with DHE due to the high level 
background fluorescence. In contrast, RASM cells incubated 
with D-DHE had very low levels of background fluorescence 
and generated a significant increase in fluorescence after 
stimulation with Ang II. 
Hydrocyanines 20 
The ability of hydrocyanines to detect ROS in rat aortic 
muscle (RASM) cells during angiotensin (Ang) II mediated 
cell signaling was evaluated using fluorescence spectroscopy. 
Ang II-mediated ROS production in aortic smooth muscle 
cells has been implicated in the development of atheroscle- 25 
rosis and hypertension. Fluorescence spectroscopy showed 
that hydrocyanine (e.g., Hydro-Cy3) detected ROS produc-
tion in RASM cells during Ang II-mediated cell signaling. 
For example, RASM cells incubated with Ang II and hydro-
cyanine (Hydro-Cy3, 100 µM) displayed an intense intracel- 30 
lular fluorescence, whereas RASM cells incubated with 
Hydro-Cy3 alone displayed significantly less fluorescence. 
Application of the superoxide dismutase mimetic TEMPOL 
resulted in a dramatic decrease in fluorescence from RASM 
cells treated with Hydro-Cy3 and Ang II, demonstrating that 35 
the cellular fluorescence was due to intracellular ROS pro-
duction. Administration of DHE under the same conditions 
failed to detect ROS, likely due to its high auto-fluorescence 
and poor stability. 
Administration of the hydrocyanine caused no cellular tox- 40 
icity under the experimental conditions described above nor 
at higher concentrations ( 1 mM), as determined by the trypan 
blue cell viability assay. 
Deuterocyanines 
RASM cells were stimulated with Ang II and then incu- 45 
bated with 50 µM of either hydro-Cy3 or deutero-Cy3 for 10 
minutes. Deutero-Cy3 is significantly more efficient than 
hydro-Cy3 at detecting intracellular ROS. RASM cells incu-
bated with hydro-Cy3 generated relatively higher amounts of 
background fluorescence, compared to deutero-Cy3. It is evi- 50 
dent from fluorescence measurements that hydro-Cy3 is sen-
sitive enough to detect even the ROS production by normal 
cells, causing relatively higher background fluorescence. On 
the other hand, because of the tuned reaction rate, deutero-
Cy3 can only detect the overproduction of ROS during Ang-II 55 
mediated ROS over-production. Therefore, RASM cells 
incubated with deuteron-Cy3 have negligible background 
fluorescence and generate a significant increase in fluores-
cence after stimulation with Ang II. Importantly, application 
of the superoxide dismutase mimetic TEMPOL resulted in a 60 
complete loss in fluorescence from RASM cells treated with 
deuteron-Cy3 and Ang II, demonstrating that deuteron-Cy3 
can specifically image the over-production of intracellular 
ROS production. 
D-DHE (DDE) 
The ability of D-DHE to detect ROS in rat aortic muscle 
(RASM) cells during angiotensin (Ang) II mediated cell sig-
65 
Application of the superoxide dismutase mimetic TEM-
POL resulted in a dramatic decrease in fluorescence from 
RASM cells treated with D-DHE and Ang II, demonstrating 
that the cellular fluorescence was due to intracellular ROS 
production. For DHE, the background fluorescence from 
aerial oxidation significantly hindered its effectiveness in the 
detection of ROS in cell culture. In contrast, the higher sta-
bility of D-DHE allowed for the accurate detection of the 
overproduction of ROS during the Ang-II mediated signaling 
event. 
Example 6 
Detection of ROS by Hydrocyanines in Live, 
Explanted Mouse Aortas 
The ability of hydrocyanines to detect ROS from live, 
explanted mouse aortas, after lipopolysaccharide endotoxin 
(LPS) stimulation to produce ROS, was evaluated. The detec-
tion of ROS in live tissue can provide information about ROS 
production in a physiological environment that closely 
resembles in vivo conditions. C57Bl/6 mice were treated 
with either 16 mg/kg lipopolysaccharide endotoxin (LPS) or 
PBS for 16 hours and then euthanized. The aortas of the mice 
were isolated and incubated with either Hydro-Cy3 or Hydro-
Cy3+ TEMPOL for 15 minutes. Sections of the aorta were 
made, fixed with 10% formalin, and mounted en face. Con-
focal fluorescent imaging showed that hydrocyanines can 
image ROS production in live tissue explants. For example, 
mice incubated with LPS and Hydro-Cy3 displayed signifi-
cantly higher fluorescence intensity than mice treated with 
PBS and Hydro-Cy3. 
Integrated total fluorescence intensity from the histology 
slides demonstrated that hydrocyanines can detect ROS in 
tissue. For example, the fluorescence intensity of the LPS-
treated slide was 183.2 RFU/S compared to 46.9 RFU/Sin the 
PBS-treated mice. Application ofTEMPOL (small molecule 
cell-permeable superoxide dismutase mimetic!, which 
attenuates superoxide anion and peroxynitrite-induced 
inflammation) to mouse aortas, treated with LPS, reduced the 
fluorescence to control levels. The integrated fluorescence 
intensity from TEMPOL-treatedaortas was 34.9 RFU/S dem-
onstrating that hydrocyanine fluorescence was due to ROS 
production. 
Administration ofDHE under the same conditions failed to 
detect ROS, due likely to the its high auto-fluorescence and 
poor stability. 
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Example 7 
In Vivo Detection of ROS 
The ability ofhydrocyanines to image ROS production, in 5 
vivo, generated by activated macrophages and neutrophils, in 
an LPS model of acute inflammation was evaluated. Nine 
C57Bl/6 mice were divided into three groups: Group I was 
given an intraperitoneal (i.p.) injection of LPS (1 mg in 400 
µL saline); Group II was given saline ( 400 µL); and Group III 10 
was untreated. After 6 hours, the mice were anaesthetized, 
their abdominal fur was removed, and the LPS and saline 
treated mice were injected i.p. with Hydro-Cy7 ( 5 nanomoles 
in 50 µL methanol). The mice were images as triplets, one 
from each group, using a Kodak FX in vivo images with a 700 15 
nm excitation laser and a 790 nm emission filter. Imaging 
showed that mice treated with LPS and Hydro-Cy7 had 
greater fluorescence intensity compared to mice treated with 
saline and Hydro-Cy7. The mean fluorescent intensity, from 
the abdominal area, from the three sets of mice was also 20 
quantified using Image-Pro software. The results are shown in 
FIG. 7. LPS-treated mice had approximately two-fold higher 
fluorescence intensity than the saline group. Taken together, 
these results indicate the hydrocyanines can image ROS in 
VIVO. 25 
Example 8 
Carotid Artery Ligation Causes an Increase in 
Superoxide Production and Neointima Formation 30 
36 
2. The method of claim 1, wherein oxidation of the reduced 
dye is detected by fluorescence spectroscopy. 
3. The method of claim 1, wherein the oxidation of the 
reduced dye is detected by fluorescence microscopy. 
4. The method of claim 3, wherein the oxidation of the 
reduced dye is detected by confocal laser scamiing micros-
copy. 
5. The method of claim 3, wherein the oxidation of the 
reduced dye is detected by total internal reflection fluores-
cence microscopy. 
6. The method of claim 1, wherein the reduced dye is a 
hydrocyanine. 
7. The method of claim 6, wherein the reduced dye is a 
deuterocyanine. 
8. The method of claim 1, wherein the hydrocyanine or 
deuterocyanine is selected from the group consisting of: 
a) 
wherein Xis hydrogen; halogen; C1_20 alkyl; aryl; -OR, 
where R is C1 _20 alkyl or aryl; hydroxyl; -NRsR6 , 
where Rs and R6 are independently hydrogen, C1_20 
alkyl or aryl; --CN, -SH; -N02 ; -S-C1_20 alkyl; 
-S-aryl; aryl, -COOH; 
35 --COH; -COR or -COOR, where R is defined above; or 
--CONR13R14, wherein R13 and R14 are independently 
hydrogen or R as defined above; 
Mice were anesthetized with ketamine/xylazine and their 
left carotid arteries were exposed and tied with a 6-0 silk 
suture 1 cm below the bifurcation as described in the litera-
ture. The control was sham operated mice. The mice were 
sacrificed 14 days after ligation and their carotid arteries were 
isolated and frozen, enzymatically-intact, and 30 µm-thick 
sections of sham operated and injured carotid arteries were 
made. The frozen sections were incuvated with DHE (10 
µmol/L) in PBS for 30 minutes at 37° C. in a humidified 40 
chamber protected form light. DHE is oxidized on reaction 
with superoxide to ethidium bromide, which binds to DNA in 
the nucleus and fluoresces red. The DHE stained slides were 
imaged on a confocal microscope. The ethidium bromide 
fluorescence was detected using a 543 nm He-Ne laser for 45 
excitation and a 560 nm long pass filter for emission. The 
autofluorescence of the elastic laminae was detected using a 
488 nmAr laser for excitation combined with a 500-550 nm 
band pass filter for emission. ROS production increased dra-
matically during carotid ligation as evidenced by increased 50 
red fluorescence compared to the sham mice. Histological 
analysis revealed that carotid ligation generates intense 
neointima formation, which is a hallmark of atherosclerotic 
diseases, and that neointima formation correlates with 
increased ROS production. 
Unless defined otherwise, all technical and scientific 
Winos used herein have the same meanings as commonly 
understood by one of skill in the art to which the disclosed 
invention belongs. 
We claim: 
55 
60 
1. A method of detecting reactive oxygen species, the 
method comprising contacting cells, cell cultures, tissues, 
organs, biological fluids, or combinations thereof, with an 
effective amount of one or more reduced dyes selected from 
the group consisting ofhydrocyanines, deuterocyanines, and 65 
combinations thereof and determining if the reduced dye has 
been oxidized. 
R1 -R4 are independently hydrogen, C1_20 alkyl, C1_20 alkyl 
sulfate, cl-20 alkyl carboxylate; cl-20 alkyl amino; aryl, 
benzyl, oligoethylene glycol, or polyethylene glycol; 
Rs and R6 are independently hydrogen; hydroxyl; ---OR8 ; 
-NH2 ; -NHR9 ; -NR10R1 u C1 _20 alkyl, C1_20 alkyl 
sulfonate, C1_20 alkyl carboxylic acid or carboxylate; 
C1_20 alkyl amino or quatemized amino; -COOH; 
--C02 - or -S03 -; wherein R8 -R11 are the same as R; 
oligoethylene glycol, or polyethylene glycol; 
n is an integer from 1-5; 
R12 is H or D; and 
the benzene ring represented by dotted lines is optional; 
(b) 
wherein X is hydrogen; halogen; C1_20 alkyl; aryl; -OR, 
where R is C1_20 alkyl or aryl; hydroxyl; -NRsR6 , where Rs 
and R6 are independently hydrogen, C1_20 alkyl or aryl; 
--CN, -SH; -N02 ; -S--C1 _20 alkyl; -S-aryl; aryl, 
-COOR; -COH; --COR or -COOR, where R is defined 
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above; or ---CONR12R13, wherein R12 and R13 are indepen-
dently hydrogen or R as defined above; 
R1 and R2 are independently hydrogen, C1 _20 alkyl, C1_20 
alkyl sulfonate, C1 _20 alkyl carboxylic acid or carboxy-
late; C1 _20 alkyl amino or quatemized amino; aryl, ben- 5 
zyl, oligoethylene glycol, or polyethylene glycol; 
R3 and R4 are independently hydrogen; hydroxyl; ---OR7 ; 
-NH2 ; -NHRs; -NR9 R10, C1_20 alkyl, C1_20 alkyl 
sulfate, cl-20 alkyl carboxylate; cl-20 alkyl amino; 
--COOR; -Co2 - or -S03 -; wherein R7 -R10 are the 
10 
same as R; oligoethylene glycol, or polyethylene glycol; 
n is an integer from 1-5; 
R11 is Hor D, and 
the benzene ring represented by dotted lines is optional; 15 
(c) 
20 
25 
wherein X is hydrogen; halogen; C1_20 alkyl; aryl; -OR, 
where R is C1 _20 alkyl or aryl; hydroxyl; -NRsR6 , where Rs 30 
and R6 are independently hydrogen, C1_20 alkyl or aryl; 
-CN, -SH; -N02 ; -S---C1 _20 alkyl; -S-aryl; aryl, 
-COOH; -COH; 
-CORor 
-COOR, where R is defined above; or -CONR12R13 , 35 
wherein R12 and R13 are independently hydrogen or R as 
defined above; 
R1 and R2 are independently hydrogen, C1 _20 alkyl, C1_20 
alkyl sulfonate, C1 _20 alkyl carboxylic acid or carboxy-
late; C1 _20 alkyl amino or quatemized amino; aryl, ben- 40 
zyl, oligoethylene glycol, or polyethylene glycol; 
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---COH; -COR or 
--COOR, where R is defined above; or -CONR17R1s, 
wherein R17 and R1s are independently hydrogen or R as 
defined above; 
R1 and R2 are independently hydrogen, C1_20 alkyl, C1_20 
alkyl sulfonate, C1 _20 alkyl carboxylic acid or carboxy-
late; C1_20 alkyl amino or quatemized amino; aryl, ben-
zyl, oligoethylene glycol, or polyethylene glycol; 
R3 and R4 are independently hydrogen; hydroxyl; -OR12 ; 
-NHR13 ; 
-NR14R1s, C1 _20 alkyl, C1_20 alkyl sulfate, C1 _20 alkyl car-
boxylate; C1 _20 alkyl amino; -COOH; -C02 - or -S03 -; 
wherein R12-R1s are the same as R; oligoethylene glycol, or 
polyethylene glycol; 
Rs-Rs are independently hydrogen or C1 _20 alkyl; 
n is an integer from 1-5; 
R16 is Hor D; and 
the benzene ring represented by dotted lines is optional, 
wherein if the benzene ring is not present, R16 is D; 
(e) 
wherein Xis hydrogen; halogen; C1_20 alkyl; aryl; -OR, 
where R is C1 _20 alkyl or aryl; hydroxyl; -NRsR6 , 
where Rs and R6 are independently hydrogen, C1_20 
alkyl or aryl; -CN, -SH; -N02 , -S---C1 _20 alkyl; 
-S-aryl; aryl, -COOH; 
---COH; -COR or --COOR, where R is defined above; or 
---CONR16R17, wherein R16 and R17 are independently 
hydrogen or R as defined above; 
R1 and R2 are independently hydrogen, C1_20 alkyl, C1_20 
alkyl sulfonate, C1 _20 alkyl carboxylic acid or carboxy-
late; C1_20 alkyl amino or quatemized amino; aryl, ben-
zyl, oligoethylene glycol, or polyethylene glycol; 
R3 and R4 are independently hydrogen; hydroxyl; -OR11 ; 
R3 and R4 are independently hydrogen; hydroxyl; ---OR7 ; 
-NH2 ; -NHRs; -NR9 R10, C1_20 alkyl, C1_20 alkyl 
sulfate, cl-20 alkyl carboxylate; cl-20 alkyl amino; 
--COOR; -Co2 - or -S03 -; wherein R7 -R10 are the 
same as R; oligoethylene glycol, or polyethylene glycol; 
45 -NHR12; 
-NR13R14, C1 _20 alkyl, C1_20 alkyl sulfate, C1 _20 alkyl car-
boxylate; C1 _20 alkyl amino; -COOH; -C02 - or -S03 -; 
wherein R11 -R14 are the same as R; oligoethylene glycol, or 
polyethylene glycol; 
n is an integer from 1-5; 
R11 is Hor D; and 
the benzene ring represented by dotted lines is optional 
(d) 
50 
55 
60 
wherein Xis hydrogen; halogen; C1_20 alkyl; aryl; -OR, 
where R is C1_20 alkyl or aryl; hydroxyl; -NRsR6 , 
where Rs and R6 are independently hydrogen, C1_20 65 
alkyl or aryl; ---CN, -SH; -N02 , -S-C1_20 alkyl; 
-S-aryl; aryl, -COOH; 
Rs-Rs are independently hydrogen or C1 _20 alkyl; 
R1s is Hor D; and 
n is an integer from 1-5; 
(f) 
wherein Xis hydrogen; halogen; C1_20 alkyl; aryl; -OR, 
where R is C1 _20 alkyl or aryl; hydroxyl; -NRsR6 , 
where Rs and R6 are independently hydrogen, C1_20 
alkyl or aryl; ---CN, -SH; -N02 ; -S-C1_20 alkyl; 
-S-aryl; aryl, -COOH; 
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-COH; -COR or --COOR, where R is defined above; or 
-CONR12R13 , wherein R12 and R13 are independently 
hydrogen or R as defined above; 
R1 and R2 are independently hydrogen, C1 _20 alkyl, C1_20 
alkyl sulfonate, C1 _20 alkyl carboxylic acid or carboxy- 5 
late; C1 _20 alkyl amino or quatemized amino; aryl, ben-
zyl, oligoethylene glycol, or polyethylene glycol; 
R3 and R4 are independently hydrogen; hydroxyl; ---OR7 ; 
-NHR8 ; 
-NR,R10, C1_20 alkyl, C1_20 alkyl sulfate, C1_20 alkyl car- 10 
boxylate; cl-20 alkyl amino; oligoethylene glycol, or poly-
ethylene glycol; 
-COOH; ---C02 - or-S03 -; wherein R7 -R10 are the same 
as R; 
R11 is Hor D; and 
n is an integer from 1-5; 
x 
~ 
' J,q 
\ _____ / 
(g) 
15 
20 
25 
40 
R1 and R2 are independently hydrogen, C1_20 alkyl, C1_20 
alkyl sulfonate, C1 _20 alkyl carboxylic acid or carboxy-
late; C1_20 alkyl amino or quatemized amino; aryl, ben-
zyl, oligoethylene glycol, or polyethylene glycol; and 
R3 and R4 are independently hydrogen; hydroxyl; ---OR7 ; 
-NHR8 ; 
-NR9 R10, C1 _20 alkyl, C1_20 alkyl sulfate, C1_20 alkyl car-
boxylate; C1_20 alkyl amino; --COOR; -C02 - or -S03 -; 
wherein R7 -R10 are the same as R; oligoethylene glycol, or 
polyethylene glycol; 
R11 is D; and 
n is an integer from 1-5; 
(i) 
, ...... -.......... 
wherein Xis hydrogen; halogen; C1_20 alkyl; aryl; -OR, 
where R is C1 _20 alkyl or aryl; hydroxyl; -NRsR6 , 
where Rs and R6 are independently hydrogen, C1_20 
alkyl or aryl; ---CN, -SH; -N02 ; -S-C1_20 alkyl; 
-S-aryl; aryl, -COOH; 
---COH; -COR or --COOR, where R is defined above; or 
wherein Xis hydrogen; halogen; C1_20 alkyl; aryl; -OR, 
where R is C1_20 alkyl or aryl; hydroxyl; -NRsR6 , 30 
where Rs and R6 are independently hydrogen, C1_20 
alkyl or aryl; -CN, -SH; -N02 ; -S-C1_20 alkyl; 
-S-aryl; aryl, ---COOH;-COH;---COR or-COOR, 
where R is defined above; or -CONR12R13 , wherein 
R12 and R13 are independently hydrogen or Ras defined 
above; 
---CONR13R14, wherein R13 and R14 are independently 35 hydrogen or R as defined above; 
R1 and R2 are independently hydrogen, C1 _20 alkyl, C1_20 
alkyl sulfonate, C1 _20 alkyl carboxylic acid or carboxy-
late; C1 _20 alkyl amino or quatemized amino; aryl, ben-
zyl, oligoethylene glycol, or polyethylene glycol; and 
40 R3 and R4 are independently hydrogen; hydroxyl; ---OR7 ; 
-NHR8 ; 
-NR,R10, C1_20 alkyl, C1_20 alkyl sulfate, C1_20 alkyl car-
boxylate; C1_20 alkyl amino; --COOR; ---C02 - or -S03 -; 
wherein R7 -R10 are the same as R; oligoethylene glycol, or 45 polyethylene glycol; 
n is an integer from 1-5; and 
q is 0, 1, or 2; 
(h) 50 
wherein Xis hydrogen; halogen; C1_20 alkyl; aryl; -OR, 
where R is C1_20 alkyl or aryl; hydroxyl; -NRsR6 , 
where Rs and R6 are independently hydrogen, C1_20 
alkyl or aryl; -CN, -SH; -N02 ; -S-C1_20 alkyl; 
-S-aryl; aryl, -COOH; 
55 
-COH; -COR or --COOR, where R is defined above; or 65 
-CONR12R13 , wherein R12 and R13 are independently 
hydrogen or R as defined above; 
R1 -R4 are independently hydrogen, C1 _20 alkyl; C1 _20 alkyl 
sulfonate, C1_20 alkyl carboxylic acid or carboxylate; 
C1_20 alkyl amino or quaternized amino; aryl, benzyl, 
oligoethylene glycol, or polyethylene glycol; 
Rs and R6 are independently hydrogen; hydroxyl; ---ORs; 
-NH2 ;-NHR6 ;-NR7R8 , C1_20 alkyl; C1_20 alkyl sul-
fate; cl-20 alkyl carboxylate; cl-20 alkyl amino; 
--COOR; ---C02 -; or -S03 -; wherein Rs-R8 are the 
same as R; oligoethylene glycol, or polyethylene glycol; 
Y and Z are independently carbon, nitrogen or sulfur, 
wherein ifY and/or Z is carbon, the carbon is tetravalent 
having two substituents as defined above; ifY and/or Z is 
sulfur; the sulfur is divalent; and ifY and/or Z is nitro-
gen, the nitrogen is trivalent, having one substituent as 
defined above; 
R12 is Hor D; and 
the benzene ring represented by dotted lines is optional; 
wherein Xis hydrogen; halogen; C1_20 alkyl; aryl; -OR, 
where R is C1 _20 alkyl or aryl; hydroxyl; -NRsR6 , 
where Rs and R6 are independently hydrogen, C1_20 
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alkyl or aryl; -CN, -SH; -N02 ; -S-C1_20 alkyl; 
-S-aryl; -COOR; --COH; 
-COR or -COOR, where R 
-CONR13R14, wherein R13 and 
is defined above; or 
R14 are independently 
42 
9. The method of claim 8, wherein the hydrocyanine or 
deuterocyanine is a compound of formula (d). 
10. The method of claim 9, wherein the benzene ring is 
absent. 
hydrogen or R as defined above; 5 11. The method of claim 10, wherein X=H, R1 and 
R1 and R2 are independently hydrogen, C1 _20 alkyl; C1_20 
alkyl sulfonate, C1 _20 alkyl carboxylic acid or carboxy-
late; C1 _20 alkyl amino or quatemized amino; aryl, ben-
zyl, oligoethylene glycol, or polyethylene glycol; 
R3 and R4 are independently hydrogen; hydroxyl; ---OR5 ; 
10 
-NH2 ;-NHR6;-NR7R8 , C1 _20 alkyl; C1_20 alkyl sul-
fonate, cl-20 alkyl carboxylic acid or carboxylate; cl-20 
alkyl amino or quatemized amino; -COOR; --C02 -; 
or -S03 -; wherein R5 -R8 are independent selected 
from the group consisting of C1 _20 alkyl or aryl; oligo-
15 
ethylene glycol, or polyethylene glycol; 
R2=methyl, ethyl, or (CH2 ) 4 S03Na, R3 and R4 =H, 
R5 -R8=methyl, and R16=D or H. 
12. The method of claim 9, wherein the benzene ring is 
present. 
13. The method of claim 12, wherein X=H, R1 and 
R2=methyl, ethyl, or (CH2 ) 4 S03Na, R3 and R4 =H, 
R5 -R8=methyl, and R16=D or H. 
14. The method of claim 8, wherein the hydrocyanine or 
deuterocyanine is a compound of formula (g). 
15. The method of claim 14, wherein X=Cl, q=2, n=l, R3 
and R4 =H, R1 and R2=(CH2 ) 4 S03Na, and R11 is hydrogen or 
deuterium. Z is carbon, nitrogen, sulfur, or oxygen, wherein ifY and/or 
Z is carbon, the carbon is tetravalent having two sub-
stituents as defined above; ifY and/or Z is sulfur and/or 
oxygen; the sulfur and/or oxygen is divalent; and ifY 
and/or Z is nitrogen, the nitrogen is trivalent, having one 
substituent as defined above; 
16. The method of claim 1, wherein the cells tissue bio-
logical fluids, or combinations thereof are conta~ted wi~h the 
20 one or more reduced dyes in vitro. 
R12 is Hor D; and 
the benzene ring represented by dotted lines is optional. 
17. The method of claim 1, wherein the cells tissue bio-
logical fluids, or combinations thereof are conta~ted wi~h the 
one or more reduced dyes in vivo. 
* * * * * 
